<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1370900</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1370900</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity</article-title>
<alt-title alt-title-type="left-running-head">Cao et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1370900">10.3389/fphar.2024.1370900</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Cao</surname>
<given-names>Gang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/573521/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hu</surname>
<given-names>ShaoQi</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ning</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dou</surname>
<given-names>Xinyue</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Chuan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1711674/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zeping</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sang</surname>
<given-names>Xianan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Qiao</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Jiangnan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hao</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1005933/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Han</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2630935/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Pharmacy</institution>, <institution>Zhejiang Chinese Medical University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/196659/overview">Rolf Teschke</ext-link>, Hospital Hanau, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1209291/overview">Peng Zhang</ext-link>, Guangzhou University of Chinese Medicine, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/534956/overview">Kun Chen</ext-link>, University of Science and Technology of China, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xin Han, <email>xinhan@zcmu.edu.cn</email>; Min Hao, <email>hao_min0509@163.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1370900</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>03</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Cao, Hu, Ning, Dou, Ding, Wang, Wang, Sang, Yang, Shi, Hao and Han.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Cao, Hu, Ning, Dou, Ding, Wang, Wang, Sang, Yang, Shi, Hao and Han</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Osteoporosis characterized by decreased bone density and mass, is a systemic bone disease with the destruction of microstructure and increase in fragility. Osteoporosis is attributed to multiple causes, including aging, inflammation, diabetes mellitus, and other factors induced by the adverse effects of medications. Without treatment, osteoporosis will further progress and bring great trouble to human life. Due to the various causes, the treatment of osteoporosis is mainly aimed at improving bone metabolism, inhibiting bone resorption, and promoting bone formation. Although the currently approved drugs can reduce the risk of fragility fractures in individuals, a single drug has limitations in terms of safety and effectiveness. By contrast, traditional Chinese medicine (TCM), a characteristic discipline in China, including syndrome differentiation, Chinese medicine prescription, and active ingredients, shows unique advantages in the treatment of osteoporosis and has received attention all over the world. Therefore, this review summarized the pathogenic factors, pathogenesis, therapy limitations, and advantages of TCM, aiming at providing new ideas for the prevention and treatment of OP.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FPHAR_fphar-2024-1370900_wc_abs.tif"/>
</p>
</abstract>
<kwd-group>
<kwd>osteoporosis</kwd>
<kwd>pathogenesis</kwd>
<kwd>pathogenic factors</kwd>
<kwd>traditional Chinese medicine</kwd>
<kwd>treatment</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Ethnopharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Osteoporosis (OP), characterized by the decrease in bone mineral density (BMD) and disorders of the bone microstructure, is a chronic metabolic bone disease (<xref ref-type="bibr" rid="B79">Noh et al., 2020</xref>). OP is a result of the imbalance of bone homeostasis that is maintained by coordinated cycles of bone resorption and formation and can contribute to the increase in bone fragility as well as the risk of fractures (<xref ref-type="bibr" rid="B24">El-Gazzar and H&#xf6;gler, 2021</xref>; <xref ref-type="bibr" rid="B163">Zhang et al., 2023</xref>). These fragility fractures lead to a disproportionately high mortality rate and drastically reduce the quality of life, all of which make osteoporosis a growing and enormous threat to public health that affects 200 million people worldwide (<xref ref-type="bibr" rid="B77">Mu&#xf1;oz et al., 2020</xref>). From the perspective of etiology, osteoporosis can be divided into two types: primary and secondary (<xref ref-type="bibr" rid="B22">Eastell et al., 2016</xref>; <xref ref-type="bibr" rid="B17">Compston et al., 2019</xref>). Among them, primary osteoporosis is a result of aging, and its most common form is postmenopausal osteoporosis (PMOP), which is caused by the decrease in estrogen secretion after menopause (<xref ref-type="bibr" rid="B17">Compston et al., 2019</xref>), while secondary osteoporosis occurs when BMD is reduced by other factors such as drugs (<xref ref-type="bibr" rid="B17">Compston et al., 2019</xref>; S., 2011). Based on various induction factors of osteoporosis, a series of therapeutic drugs for osteoporosis have been developed for clinical practice, including estrogen, calcitonin, bisphosphonates, and teriparatide (<xref ref-type="bibr" rid="B49">Khosla and Hofbauer, 2017</xref>). Among these, estrogens, used in the prevention and therapy of osteoporosis, have certain side effects, including increased risk of cardiovascular events and breast cancer (<xref ref-type="bibr" rid="B97">Rossouw et al., 2002</xref>). Calcitonin was developed based on animal and human studies and is now rarely used for the treatment of osteoporosis due to its limited efficacy on osteoporosis and concerns that its long-term use may increase the risk of cancer (<xref ref-type="bibr" rid="B14">Chesnut et al., 2000</xref>). In addition, bisphosphonates are the most widely used drugs, but poor adherence is a major limiting factor for their treatment of osteoporosis, which is largely associated with gastrointestinal adverse events (<xref ref-type="bibr" rid="B18">Cramer et al., 2007</xref>). Moreover, treatment with high doses of teriparatide may increase the risk of developing osteosarcoma in growing rodents (<xref ref-type="bibr" rid="B112">Vahle et al., 2016</xref>). Therefore, it is urgent to seek some effective drugs with few side effects for the treatment of osteoporosis. Despite some progress in the treatment of osteoporosis, the side effects of these drugs are of concern (<xref ref-type="bibr" rid="B49">Khosla and Hofbauer, 2017</xref>). Therefore, exploring the pathogenesis of OP and finding its therapeutic drugs are crucial.</p>
<p>OP is closely associated with aging, endocrine diseases, chronic kidney diseases, gastrointestinal diseases, and so on (<xref ref-type="bibr" rid="B52">Lane, 2006</xref>). It is worth mentioning that osteoporosis is often accompanied by pain, spinal deformity, and fracture, even limitation of movement and disability, all of which seriously affect the quality of daily life (<xref ref-type="bibr" rid="B111">Tsai et al., 2019</xref>). Under the inducement of these factors, the formation of OP is associated with osteoblasts that maintain functional cells of bone formation and osteoclasts that participate in bone resorption. Osteoblasts are the main functional cells in bone for bone resorption. Osteoblasts play an important role in the synthesis, secretion, and mineralization of the bone matrix, while osteoclasts, known as bone-resorbing cells, are a component of bone tissue and mainly regulate the function of bone resorption (<xref ref-type="bibr" rid="B15">Chotiyarnwong and McCloskey, 2020</xref>). In OP, osteoclasts accomplish the transformation from bone resorption to bone formation by transmitting coupling signals to osteoblasts (<xref ref-type="bibr" rid="B44">Ikebuchi et al., 2018</xref>). During this process, the receptor activator of NF-&#x3ba;B (RANK)/receptor activator of the NF-&#x3ba;B ligand (RANKL)/osteoprotegerin (OPG) axis plays a key role (<xref ref-type="bibr" rid="B167">Zhao et al., 2020</xref>). Studies showed that the inhibition of RANKL can be a therapeutic strategy for excessive bone resorption, such as recombinant, which is still in the research stage due to its uncertain side effects. Therefore, it is urgent to seek some effective drugs with few side effects for the treatment of OP (<xref ref-type="bibr" rid="B39">He et al., 2019</xref>).</p>
<p>Traditional Chinese medicine (TCM), with few side effects, has unique advantages in the treatment of chronic disease. Studies showed that TCM has a long history in the prevention and treatment of OP (<xref ref-type="bibr" rid="B160">Zhang et al., 2016</xref>), such as <italic>Eucommiae Folium</italic>, <italic>Cornus officinalis</italic>, and <italic>Radix Angelicae sinensis</italic>. Moreover, TCM treatment based on syndrome differentiation is the accumulation of clinical practice gathered over centuries (<xref ref-type="bibr" rid="B30">Fu et al., 2021</xref>) and has specific advantages in the treatment of OP. In this review, we summarized the pathogenic factors, pathogenesis, therapy limitations, and advantages of TCM, aiming at providing new ideas for the prevention and treatment of OP.</p>
</sec>
<sec id="s2">
<title>2 Pathogenic factors of osteoporosis</title>
<sec id="s2-1">
<title>2.1 Aging is a major cause of osteoporosis</title>
<p>The skeletal system grows rapidly, mainly from the postnatal period to puberty after birth and adolescence, reaches its peak at about 35 years of age (<xref ref-type="bibr" rid="B123">Wayne Sampson, 2002</xref>), and then, gradually decreases with age in both men and women (<xref ref-type="bibr" rid="B140">Yamakawa et al., 2020</xref>). Therefore, aging is a baseline risk factor in the development of OP and bone fracture, as well as a predictor of poor outcomes after fracture (<xref ref-type="bibr" rid="B114">VanderWalde and Hurria, 2011</xref>). In women, primary OP, also called postmenopausal OP, is mainly induced by menopause plus the cessation of ovarian function, specifically, a decline in postmenopausal ovarian endocrine function, resulting in the decrease in Es level and leading to greater bone resorption than bone formation (<xref ref-type="bibr" rid="B128">Wu et al., 2021</xref>). Of note, up to one-third of fragility fractures occur in older men and are usually accompanied by severe osteoporotic fractures, especially hip fractures. Due to these problems, OP in the elderly is an important threat to the life quality of individual patients and a huge burden to society (<xref ref-type="bibr" rid="B48">Kaufman, 2021</xref>). Therefore, exploring the pathogenesis of aging-related OP is crucial for the treatment of OP. Qadir et al. stated that due to aging, bone marrow stromal cells were more likely to differentiate into adipocytes rather than osteoblasts, which contributes to the decrease in bone formation, leading to the development of senile OP (<xref ref-type="bibr" rid="B88">Qadir et al., 2020</xref>). Moreover, with aging, the excessive accumulation of reactive oxygen species (ROS), interleukin-6 (IL-6), tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), and other cytokines in cells will affect the differentiation of osteoclasts and the formation of osteoblasts, leading to osteoporotic bone loss (<xref ref-type="bibr" rid="B149">Yu and Wang, 2016</xref>). Therefore, inflammation is another cause of osteoporosis.</p>
</sec>
<sec id="s2-2">
<title>2.2 Inflammation is involved in the development of osteoporosis</title>
<p>Innate immune cells are the major source of proinflammatory factors, such as IL-6 and TNF-&#x3b1;, and can immediately respond to various challenges in the body, which has been considered one of the main inducements of skeletal diseases (<xref ref-type="bibr" rid="B38">Hato and Dagher, 2015</xref>). In OP, osteoblasts undergo programmed necrosis and release NOD-like receptor protein 3 (NLRP3), thereby resulting in inflammatory responses. During these processes, IL-1&#x3b2; and IL-18 were cleaved by caspase-1 and turned into mature forms that could be released into the extracellular environment, which promoted excessive bone resorption (<xref ref-type="bibr" rid="B115">Vijayaraj et al., 2021</xref>). Moreover, other immune cells, such as DCs, macrophages, and monocytes, can also take part in osteoclast formation because they share a common developmental niche (<xref ref-type="bibr" rid="B87">Ponzetti and Rucci, 2019</xref>). Analogous eosinophils, mast cells, and neutrophils could also contribute to the development of OP (<xref ref-type="bibr" rid="B152">Yu et al., 2015</xref>; <xref ref-type="bibr" rid="B93">Ragipoglu et al., 2020</xref>). It can be seen that inflammation plays a critical role in OP due to its role in bone loss and osteoblast function (<xref ref-type="bibr" rid="B1">Amarasekara et al., 2015</xref>), which is characterized by BMD reduction and the production of cytokines in diseases such as periodontitis (<xref ref-type="bibr" rid="B150">Yu and Wang, 2022</xref>) and rheumatoid arthritis (RA) (<xref ref-type="bibr" rid="B28">Forsblad D&#x27;Elia et al., 2003</xref>).</p>
</sec>
<sec id="s2-3">
<title>2.3 OP is often a complication of diabetes mellitus</title>
<p>OP is also closely associated with diabetes mellitus (DM), which is characterized by polyphagia, polyuria, and hyperglycemia (<xref ref-type="bibr" rid="B27">Fang et al., 2021</xref>). DM is usually divided into two types: type 1 diabetes mellitus (T1DM) and type 2 diabetes. Among them, T1DM is known as insulin-dependent diabetes and can induce bone loss due to calcium and phosphorus imbalance (<xref ref-type="bibr" rid="B53">Lecka-Czernik, 2017</xref>), while type 2 diabetes is non-insulin-dependent diabetes mellitus that is considered a risk factor for OP (<xref ref-type="bibr" rid="B5">Barrett-Connor E, 1992</xref>), mainly due to that increased obesity in diabetic patients will affect the function of osteoblasts and osteoclasts (<xref ref-type="bibr" rid="B94">Rathinavelu et al., 2018</xref>). In addition, a variety of chronic complications related to diabetes mellitus, such as diabetic liver disease (fatty liver), diabetic nephropathy (<xref ref-type="bibr" rid="B84">Paschou et al., 2017</xref>), microvascular disease (<xref ref-type="bibr" rid="B99">Samakkarnthai et al., 2020</xref>), and diabetic neuropathy (<xref ref-type="bibr" rid="B84">Paschou et al., 2017</xref>), can also contribute to the development of OP.</p>
</sec>
<sec id="s2-4">
<title>2.4 Other factors contribute to osteoporosis</title>
<p>In addition, other factors, such as cerebral apoplexy, breast cancer (<xref ref-type="bibr" rid="B105">Sozel and Yilmaz, 2021</xref>), decompensated cirrhosis (<xref ref-type="bibr" rid="B146">Yang and Kim, 2021</xref>), gastrointestinal disease (<xref ref-type="bibr" rid="B50">Klaus et al., 2002</xref>), bowel disease, celiac disease, and hyperuricemia (<xref ref-type="bibr" rid="B55">Lee et al., 2021</xref>) and its induction divisors (smoking, alcohol, virus, etc.) (<xref ref-type="bibr" rid="B70">Lo et al., 2020</xref>), can also contribute to various degrees of osteoporosis. It is worth mentioning that the current treatment drugs for the above diseases include rosiglitazone, bisphosphonate (<xref ref-type="bibr" rid="B101">Sheu et al., 2022</xref>), unfractionated heparin, and low-molecular-weight heparin (<xref ref-type="bibr" rid="B157">Zhang B. et al., 2021</xref>). Proton pump inhibitors also play critical roles in the development of OP. In addition, a study showed that weight was also closely associated with the incidence of OP (<xref ref-type="bibr" rid="B3">Andreoli et al., 2011</xref>), which is due to that a high body mass index is related to high BMD and reduction of fracture risk in postmenopausal females (<xref ref-type="bibr" rid="B110">Tariq et al., 2017</xref>). Furthermore, other factors that affect body weight are also involved in the development of OP, such as nutrition and exercise. To be specific, malnutrition caused by low-protein diets can reduce the expression of insulin-like growth factor 1 (IGF-1), suppress the absorption of intestinal calcium and phosphorus, and inhibit bone calcification (<xref ref-type="bibr" rid="B78">Mu&#xf1;oz and Argente, 2002</xref>); exercise can regulate the biological activity of osteoblasts, increase mass accumulation of bone, and prolong bone turnover rate; furthermore, long-term plus regular weight-bearing exercise can increase BMD and reduce bone loss (<xref ref-type="bibr" rid="B106">Stein and Shane, 2003</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Pathogenic factors of osteoporosis, such as aging, inflammation, and diabetes mellitus, could contribute to the development of osteoporosis.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g001.tif"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>3 Treatment of OP</title>
<p>Due to the variety of pathogenic factors of OPG, the application of TCM and Western medicine in the treatment of OP is also very different. For Western medicine, the treatment strategy for OP is mainly to prevent fractures, and reducing bone resorption or stimulating bone formation in this process are common means (<xref ref-type="bibr" rid="B33">Gennari et al., 2020</xref>). Based on this, the main therapeutic drugs for OP are anti-absorption drugs and anabolic agents (<xref ref-type="bibr" rid="B60">Li et al., 2021</xref>). Among them, bisphosphonates are the most widely used anti-bone resorption drugs, which can reduce bone turnover markers to a lower concentration before menopause and have achieved considerable results in reducing the fracture rate and the treatment of OP (<xref ref-type="bibr" rid="B23">Eastell and Szulc, 2017</xref>). However, the study revealed that the patients who were treated with bisphosphonates for 3 years or more were at an increased risk for osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs), but the absolute risks were low (<xref ref-type="bibr" rid="B4">Ayers et al., 2023</xref>). Moreover, poor adherence to bisphosphonate therapy is a major limiting factor in OP treatment, which is largely associated with gastrointestinal adverse events (<xref ref-type="bibr" rid="B82">Pagnotti et al., 2019</xref>). In addition, treatment using bisphosphonates can also cause other side effects, such as fever and myalgia, especially after the treatment is started (<xref ref-type="bibr" rid="B4">Ayers et al., 2023</xref>). It is worth noting that these side reactions caused by bisphosphonates can be alleviated by TCM, which is due to the characteristics of TCM with multiple approaches, multiple targets, and the four diagnostic methods of TCM, namely, observation, listening, asking, and cutting (<xref ref-type="bibr" rid="B160">Zhang et al., 2016</xref>).</p>
<p>Compared with the single treatment using bisphosphonates, TCM can develop personalized treatment plans according to the different physiques of patients. Specifically, for patients with poor spleen and stomach function, accompanied by general weakness, drugs with properties of strengthening the spleen and replenishing qi can be used; for patients with spleen and stomach disorders, accompanied by diarrhea and abdominal pain, drugs with an effect of strengthening the spleen and stopping diarrhea can be used; TCM can also improve blood circulation, promote the delivery of bone nutrients, and alleviate pain in patients with OP through methods such as acupuncture and moxibustion (<xref ref-type="bibr" rid="B170">Zhuo et al., 2022</xref>). Therefore, TCM has unique advantages in the treatment of OP, including alleviating symptoms, improving prognosis, and reducing fracture incidence.</p>
<p>However, the mechanism and pharmacodynamic components of TCM on OP treatment are still unclear, and the main limiting factors of its development are also problems that need to be solved urgently.</p>
</sec>
<sec id="s4">
<title>4 TCM in the treatment of OP based on syndrome differentiation</title>
<p>TCM has a long history of being used to prevent and treat osteoporosis. According to the pathology and clinical manifestations of OP in modern medicine, OP in TCM can be classified into the scope of &#x201c;ostealgia (Gu bi)&#x201d; and &#x201c;atrophic debility of bones (Gu wei)&#x201d; according to &#x201c;Nei jing.&#x201d; Among them, kidney deficiency, blood stasis, and qi and yin deficiency are the main pathogenesis, and the disease location is bone. The nature is &#x201c;deficiency of kidney essence, spleen deficiency, and nourishment loss,&#x201d; whose features are blood stasis block (<xref ref-type="bibr" rid="B76">Mohammad et al., 2018</xref>). For the treatment of this disease, some TCM preparations, acupoint application, acupuncture, massage, and other TCM therapies are also applied to improve BMD. According to the TCM theory, bone diseases are closely related to the health status of the kidney. Therefore, people with kidney qi deficiency and kidney yin deficiency are more prone to suffer from OP. Traditional treatments mainly use the method of tonifying the kidney and strengthening the bone based on syndrome differentiation. In addition to drug treatment, acupuncture and acupoint application can effectively prevent and treat the disease. The research of single Chinese medicine and effective components mainly involves Epimedii Folium, Eucommiae Cortex, and Salviae Miltiorrhizae Radix et Rhizoma (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Main single herbs for treating osteoporosis.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g002.tif"/>
</fig>
<sec id="s4-1">
<title>4.1 Herbal extracts</title>
<p>Chinese herbal medicine formulations with the advantages of multiple components and targets have been widely considered by researchers in the treatment of chronic disease (<xref ref-type="bibr" rid="B19">Cui et al., 2010</xref>). Bellavia et al. revealed the potential effects of flavonoids in bone resorption and promoting bone formation via a review of literature records in the last 5&#xa0;years (<xref ref-type="bibr" rid="B6">Bellavia et al., 2021</xref>). In addition, saponins, iridoid glycosides, and lignans in Chinese herbal medicine also showed certain therapeutic effects on OP, whose mechanism was associated with Wnt/&#x3b2;-catenin, BMP/Smad, and mitogen-activated protein kinase (MAPK) pathways, RANKL/OPG signaling, and others (<xref ref-type="bibr" rid="B160">Zhang et al., 2016</xref>). For example, the dry leaf of <italic>Epimedium brevicornu</italic> Maxim. has a long history in the treatment of bone diseases in China due to its effect of tonifying kidney yang and strengthening muscles and bones. According to modern research, total flavonoids of <italic>Epimedium brevicornu</italic> Maxim. can treat osteoporotic distal radius fractures (<xref ref-type="bibr" rid="B138">Xue et al., 2016</xref>). Icariin (ICA), as the main active flavonoid glycoside in <italic>Epimedium brevicornu</italic> Maxim., has the effect of enhancing osteogenic activity through the regulation of the JNK/c-Jun signaling pathway, Wnt/&#x3b2;-catenin pathway, and Notch signaling pathway (<xref ref-type="bibr" rid="B43">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="B137">Xu et al., 2019</xref>; Yu et al., 2020). In addition, Eucommiae Folium extract can promote the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) by regulating the Wnt/&#x3b2;-catenin signaling pathway and decreasing RANKL-induced bone resorption-related genes, such as TRAP (<xref ref-type="bibr" rid="B13">Cheng et al., 2019</xref>). The aqueous extract of Eucommiae Folium after salt roasting can promote the proliferation and differentiation of MC3T3-E1 cells, elevate the OPG level, and inhibit the secretion and expression of RANKL protein by regulating ERK, NF-&#x3ba;B, AKT pathways (<xref ref-type="bibr" rid="B35">Guan et al., 2021</xref>). Furthermore, Salviae Miltiorrhizae Radix et Rhizoma, also known as Danshen in Chinese, has a long history of being used to treat bone disorders (<xref ref-type="bibr" rid="B36">Guo et al., 2014</xref>). With the development of modern analytical techniques, many compounds have been isolated and identified from Danshen. Tanshinol is one of these compounds, and importantly, it can also play a role in reducing bone formation disorders through KLF15/PPAR&#x3b3;2 signaling (<xref ref-type="bibr" rid="B147">Yang Y.-j. et al., 2018</xref>). In addition, tanshinones are thought to inhibit osteoclast differentiation and may be a candidate for the treatment of OP (<xref ref-type="bibr" rid="B57">Lee et al., 2005</xref>). Moreover, Danshen has been reported to combine with Puerariae Lobatae Radix to alleviate OP through autophagy and oxidative stress-mediated osteoclast differentiation (<xref ref-type="bibr" rid="B90">Qin et al., 2021</xref>). Drynariae Rhizoma is introduced to improve glucocorticoid-induced OP by regulating the activity of osteoblasts and osteoclasts. Naringin has been identified as an effective anti-OP component of Drynariae Rhizoma (<xref ref-type="bibr" rid="B85">Peng C.-H. et al., 2022</xref>). Like naringin, the other five flavonoids, namely, aglycones, kurarinone, kushennol F, xanthogalenol, and sophoraflavanone G, have a potential protective effect against ovariectomized-induced osteoporosis, which may be related to the activation of endoplasmic reticulum signaling pathways (<xref ref-type="bibr" rid="B120">Wang et al., 2011</xref>). Achyranthis Bidentatae Radix is a TCM used to treat OP (<xref ref-type="bibr" rid="B159">Zhang M. et al., 2018</xref>). Polysaccharides have been the most studied in all components of Achyranthis Bidentatae Radix, and it has been reported that these polysaccharides can promote bone formation and, thus, play a potential role in anti-OP therapy (<xref ref-type="bibr" rid="B162">Zhang S. et al., 2018</xref>). In addition, Dipsaci Radix is a typical Chinese medicine used to treat OP by regulating immune-related pathways. In this study, ursolic acid and beta-sitosterol were shown to be the effective compounds (<xref ref-type="bibr" rid="B155">Zhang W. et al., 2019</xref>). Sweroside is the major active iridoid glycoside isolated from Dipsaci Radix. It has been reported that sweroside can exert beneficial effects on anti-OP by interacting with the membrane estrogen receptor-&#x3b1; and GPR30 to activate the p38 signaling pathway (<xref ref-type="bibr" rid="B130">Wu et al., 2020</xref>). As a triterpenoid saponin, asperosaponin VI exhibits anti-osteoclastogenic activity by inhibiting RANKL-induced osteoclast differentiation and function (<xref ref-type="bibr" rid="B68">Liu et al., 2019</xref>). Some compounds in Psoraleae Fructus display anti-OP activity by activating the ER-Wnt-&#x3b2;-catenin signaling pathway, among which isoflavones have the strongest activity (<xref ref-type="bibr" rid="B8">Cai et al., 2021</xref>). As a representative flavonoid, corylifol A can reduce ROS production through the activation of Nrf2, leading to the inhibition of osteoclast production and activation (<xref ref-type="bibr" rid="B58">Li et al., 2024</xref>). Similarly, corylin is also a flavonoid in Psoraleae Fructus, which increases the expression of osteogenic markers such as Runt-related transcription factor 2 (Runx2), osterix, type I collagen (Col1), and alkaline phosphatase (ALP), thus targeting the treatment of osteoblast-mediated OP (Yu TX. Y. et al., 2020). Cistanches Herba is an edible Chinese medicine that inhibits the RANKL/Rank-induced activation of downstream NF-&#x3ba;B and PI3K/AKT pathways and blocks the activity of the key osteoclastogenic proteins NFAT2 and c-Fos (<xref ref-type="bibr" rid="B154">Zhang B. et al., 2019</xref>). Cistanches Herba polysaccharide reduces RANKL-mediated ROS production in osteoclasts, which impairs osteoclastogenesis and bone resorption (<xref ref-type="bibr" rid="B103">Song et al., 2018</xref>). Cistanoside A is a phenylethanol glycoside compound isolated from Cistanches Herba, which has the potential to treat OP by downregulating TRAF6 (<xref ref-type="bibr" rid="B136">Xu et al., 2017</xref>). In summary, numerous TCM formulations and compounds derived from them have showed potential therapeutic effects in the prevention and treatment of OP (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Single herbs in osteoporosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Single herbs</th>
<th align="center">Anti-osteoporotic compounds</th>
<th align="center">Mechanism</th>
<th align="center">Pathway</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="center">
<italic>Epimedium brevicornu</italic> Maxim</td>
<td rowspan="4" align="center">Icariin, epimedin A, epimedin B, epimedin C, and icariside &#x2161;</td>
<td align="center">Enhance osteogenic activity</td>
<td align="center">EphB4/Ephrin-B2</td>
<td align="center">
<xref ref-type="bibr" rid="B43">Huang et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Inhibit apoptosis in human MSCs</td>
<td align="center">JNK/c-Jun</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Cheng et al. (2019);</xref> <xref ref-type="bibr" rid="B151">Yu et al. (2020b)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">Promote the proliferation and differentiation of MSCs into osteoblasts</td>
<td align="center">Wnt/&#x3b2;-catenin</td>
<td align="center">
<xref ref-type="bibr" rid="B11">Chen et al. (2016);</xref> <xref ref-type="bibr" rid="B13">Cheng et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Notch</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Cheng et al. (2019);</xref> <xref ref-type="bibr" rid="B137">Xu et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">
<italic>Eucommia ulmoides</italic> Oliv</td>
<td rowspan="2" align="center">5-(Hydroxymethyl)-2-furaldehyde</td>
<td align="center">Promote the osteogenic differentiation of BMSCs</td>
<td align="center">Wnt/&#x3b2;-catenin</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Cheng et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Promote the proliferation and differentiation of MC3T3-E1 and the ratio of OPG/RANKL</td>
<td align="center">ERK, p38MAPK, NF-&#x3ba;B, and Akt</td>
<td align="center">
<xref ref-type="bibr" rid="B35">Guan et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">
<italic>Salvia miltiorrhiza</italic> Bge</td>
<td rowspan="3" align="center">Tanshinone VI, tanshinone &#x2161;A, salvianolic acid A, salvianolic acid B, and tanshinol</td>
<td align="center">Block the expression of TRAF6 and NFTAc1 and develop osteoclast differentiation</td>
<td align="center">NF-&#x3ba;B</td>
<td align="center">
<xref ref-type="bibr" rid="B83">Park et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Activate AKT1, IL-6, VEGF-A, and mapk1 proteins and PI3K/Akt, IL-17, HIF-1, and AGE-RAGE pathways</td>
<td align="center">PI3K/Akt, IL-17, HIF-1, and AGE-RAGE</td>
<td align="center">
<xref ref-type="bibr" rid="B56">Lee et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">and regulate the osteogenic differentiation function</td>
<td align="center">Wnt/FOXO3a</td>
<td align="center">
<xref ref-type="bibr" rid="B91">Qin et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="center">
<italic>Drynaria fortunei</italic> (Kunze) J. Sm</td>
<td rowspan="4" align="center">Naringin, kurarinone, kushennol F, xanthogalenol, and sophoraflavanone G</td>
<td align="center">Promote bone formation effectively and reduce bone resorption and related gene expression</td>
<td align="center">PI3K-AKT, Wnt, and Es signaling pathways</td>
<td align="center">
<xref ref-type="bibr" rid="B31">Gan et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Promote osteogenesis</td>
<td align="center">JAK2/STAT3</td>
<td align="center">
<xref ref-type="bibr" rid="B119">Wang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Increase the expression of phosphorylated proteins</td>
<td align="center">PI3K/AKT/mTOR</td>
<td align="center">
<xref ref-type="bibr" rid="B32">Ge and Zhou (2021)</xref>
</td>
</tr>
<tr>
<td align="center">Treat osteoporotic fracture through angiogenesis</td>
<td align="center">VEGF/VEGFR-2</td>
<td align="center">
<xref ref-type="bibr" rid="B104">Song et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Achyranthes bidentata</italic> Bl</td>
<td align="center">Achyranthoside E, chikusetsusaponin &#x2163;a, momordin &#x2160;b, ecdysterone, daucosterol, quercetin, achyranthoside C dimethyl ester, achyranthoside C butyl dimethyl ester, achyranthoside E dimethyl ester, achyranthoside, and E butyl methyl ester</td>
<td align="center">Enhance the expression of OB-related genes and differentiation of OBs</td>
<td align="center">ERK signaling pathway</td>
<td align="center">
<xref ref-type="bibr" rid="B41">Hua and Zhang (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Dipsacus asper</italic> Wall. ex Henry</td>
<td align="center">Asperosaponin &#x2165;, ursolic acid, beta-sitosterol, and sweroside</td>
<td align="center">Promote VEGF, angiogenesis, and the ratio of OPG/RANKL</td>
<td align="center">RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS</td>
<td align="center">
<xref ref-type="bibr" rid="B108">Sun et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">
<italic>Psoralea corylifolia</italic> L.</td>
<td rowspan="2" align="center">Corylifol A and corylin</td>
<td align="center">Induce OB differentiation and mineralization and enhance osteogenesis and mitochondria function</td>
<td align="center">Es and Wnt/&#x3b2;-catenin signaling pathways</td>
<td align="center">
<xref ref-type="bibr" rid="B148">Yu et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="center">Inhibit adipocyteformation and differentiation</td>
<td align="center">Es and Akt/GSK-3&#x3b2;/&#x3b2;-catenin</td>
<td align="center">
<xref ref-type="bibr" rid="B9">Cao et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">
<italic>Cistanche deserticola</italic> Y. C. Ma</td>
<td rowspan="3" align="center">Cistanoside A and echinacoside</td>
<td align="center">Inhibit the differentiation of osteoclast and the corresponding bone resorption</td>
<td align="center">RANKL/RANK/TRAF6</td>
<td align="center">
<xref ref-type="bibr" rid="B155">Zhang et al. (2019b)</xref>
</td>
</tr>
<tr>
<td align="center">Promote bone formation and prevent bone resorption</td>
<td align="center">NF-&#x3ba;B and stimulation of PI3K/Akt</td>
<td align="center">
<xref ref-type="bibr" rid="B136">Xu et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">Attenuate the expression of OCs related genes and hydroxyapatite to suppress NFAT and MAPK activation</td>
<td align="center">RANKL</td>
<td align="center">Song et al. (2018b)</td>
</tr>
<tr>
<td align="center">
<italic>Cornus officinalis</italic> Sieb. et Zucc</td>
<td align="center">Gallic acid, morroniside, loganin, sweroside, flavonol kaempferol, and cornuside I</td>
<td align="center">Regulate the homeostasis of osteogenesis and osteoclast</td>
<td align="center">PI3K-AKT and Wnt/&#x3b2;-catenin</td>
<td align="center">
<xref ref-type="bibr" rid="B109">Tang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Angelica sinensis</italic> (Oliv.) Diels</td>
<td align="center">Ferulic acid, ligustilide, and guaiacol</td>
<td align="center">Promote osteoblast differentiation via the regulation of EGFR</td>
<td align="center">GPR30/EGFR pathway</td>
<td align="center">
<xref ref-type="bibr" rid="B143">Yang et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Coptis chinensis</italic> Franch</td>
<td align="center">Berberine, copisine, worenine, jatrorrhizine, and columbamine</td>
<td align="center">Promote the proliferation and differentiation of osteoblasts as well as inhibit the production of osteoclasts to promote bone regeneration</td>
<td align="center">Runx2</td>
<td align="center">
<xref ref-type="bibr" rid="B165">Zhang et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Cuscuta chinensis</italic> Lam</td>
<td align="center">Quercetin, kaempferol hyperoside, hyperin, p-hydroxycinnamic acid, and astragalin</td>
<td align="center">Alleviate the increase of bone resorption markers and the decline of osteogenic markers</td>
<td align="center">RANKL/OPG</td>
<td align="center">
<xref ref-type="bibr" rid="B75">Mo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Lycium barbarum</italic> L.</td>
<td align="center">Rutin</td>
<td align="center">Alleviate age-related bone loss</td>
<td align="center">BMPRIA/BMPRII/Noggin</td>
<td align="center">
<xref ref-type="bibr" rid="B107">Sun et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Rehmannia glutinosa</italic>
<break/>Libosch</td>
<td align="center">Catalpol and acteoside</td>
<td align="center">Prevent bone loss and enhance osteoblastic bone formation</td>
<td align="center">IGF-1/PI3K/mTOR</td>
<td align="center">
<xref ref-type="bibr" rid="B34">Gong et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Polygonum multiflorum</italic>
<break/>Thunb</td>
<td align="center">Emodin, polydatin, and 2,3,5,4&#x2032;-tetrahydroxystilbene-2-O-<italic>&#x3b2;</italic>-D-glucoside</td>
<td align="center">Ameliorate osteoporosis</td>
<td align="center">MAPK</td>
<td align="center">
<xref ref-type="bibr" rid="B66">Lin et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Curculigo orchioides</italic>
<break/>Gaertn</td>
<td align="center">Curculigoside</td>
<td align="center">Stimulate the osteogenic differentiation of MC3T3-E1 cells</td>
<td align="center">BMP and Wnt</td>
<td align="center">
<xref ref-type="bibr" rid="B116">Wang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">
<italic>Phellodendron chinense</italic>
<break/>Schneid</td>
<td align="center">Berberine</td>
<td align="center">Promote osteoblast differentiation</td>
<td align="center">p38 MAPK</td>
<td align="center">
<xref ref-type="bibr" rid="B54">Lee et al. (2008)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s4-2">
<title>4.2 Traditional Chinese medicine formula</title>
<p>&#x201c;Shen nong ben cao jing&#x201d; recorded that medicine should be in harmony with the king and minister (Jun&#x2013;chen&#x2013;zuo&#x2013;shi). Due to this theory, TCM preparations consisting of multiple herbs have attracted increasing international attention because of their characteristics and curative effects. Among these, OP Liuwei Dihuang pill (LWD), which mainly consists of <italic>Rehmannia glutinosa</italic> Libosch, <italic>Paeonia suffruticosa</italic> Andr, <italic>Dioscorea opposita</italic> Thunb<italic>.</italic>, Poria cocos (Schw.) Wolf, Alisma orientale (Sam.) Juz., and Cornus officinalis Sieb. et Zucc., was used in the treatment of OP, showing that miR-574 plays critical roles in osteoporosis, and kaempferol and quercetin actives may be the ingredients of LWD targeting MAPK1 to mediate MiR-574, thereby regulating the bone microenvironment and improving OP (<xref ref-type="bibr" rid="B69">Liu et al., 2022</xref>). Additionally, Shuai Bo et al. found that Qing&#x2019;e Pill (QEP), consisting of <italic>Eucommia ulmoides</italic> Oliv., <italic>Psoralea corylifolia</italic> L., <italic>Juglans regia</italic> L., and <italic>Allium sativum</italic> L, could improve the microstructure of cancellous bone in ovariectomized mice by increasing the expression of &#x3b2;-catenin. Further study revealed that QEP could prevent osteoblast ferroptosis and increase osteogenesis (<xref ref-type="bibr" rid="B102">Shuai et al., 2019</xref>; <xref ref-type="bibr" rid="B37">Hao et al., 2022</xref>). Yangyang et al. confirmed that Yishen Bugu Ye (YSBGY) showed potential anti-osteoporotic effects through the modulation of the osteoblast/osteoclast balance and serum concentrations of inflammatory factors (<xref ref-type="bibr" rid="B62">Li et al., 2020</xref>). As a famous Chinese medicine preparation, Erzhi Wan (EZW) has a favorable anti-OP potential, mainly through inhibiting osteoclast bone absorption (<xref ref-type="bibr" rid="B158">Zhang et al., 2008</xref>). Zuogui Pill (ZGP) is a classic kidney-tonifying drug that can promote the osteogenic differentiation of bone marrow mesenchymal stem cells, which provides a scientific basis for its effective treatment of OP (<xref ref-type="bibr" rid="B141">Yang et al., 2018a</xref>). In addition, details of other traditional Chinese medicine formulas used in OP therapy are shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Prescription in osteoporosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Prescription name</th>
<th align="center">Ingredients</th>
<th align="center">Mechanism</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Liuwei Dihuang pill (LWD)</td>
<td align="center">Rehmannia glutinosa Libosch, Paeonia suffruticosa Andr, Dioscorea opposita Thunb., Poria cocos (Schw.) Wolf, Alisma orientale (Sam.) Juz., and Cornus officinalis Sieb. et Zucc</td>
<td align="center">Improve the bone microenvironment, hormone, and enzyme activities</td>
<td align="left">
<xref ref-type="bibr" rid="B69">Liu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">Qing&#x2019;e Pill (QEP)</td>
<td align="center">Eucommia ulmoides Oliv., Psoralea corylifolia L., Juglans regia L., and Allium sativum L</td>
<td align="left">Increase &#x3b2;-catenin expression</td>
<td align="left">
<xref ref-type="bibr" rid="B102">Shuai et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">Yishen Bugu Ye (YSBGY)</td>
<td align="center">Rhizoma Drynariae, Radix Polygoni Multiflori, Poria, Radix Dipsaci, Radix Paeoniae Alba, Radix Angelica sinensis, Radix Codonopsis, Radix Rehmanniae Preparata, Rhizoma Polygonati, Fructus Lycii, Pyritum, and Pericarpium Citri Reticulatae</td>
<td align="center">Relate to regulate the OB/OC balance and inflammatory factors</td>
<td align="left">
<xref ref-type="bibr" rid="B62">Li et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Erzhi Wan (EZW)</td>
<td align="center">Ligustrum lucidum Ait. and Eclipta prostrata (L.) L</td>
<td align="center">Restraint of osteoclastic bone resorption</td>
<td align="left">
<xref ref-type="bibr" rid="B158">Zhang et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="center">Zuogui pill (ZGP)</td>
<td align="center">Rehmannia glutinosa Libosch, Dioscorea opposite Thunb, Lyciumbarbarum L., Cornus officinalis Sieb. et Zucc., Cyathula officinalis Kuan, Cuscuta chinensis Lam., <italic>Cervus elaphus</italic> Linnaeus, and Chinemys reevesii (Gray)</td>
<td align="center">Promote the differentiation of osteoblasts and osteogenesis-related genes and reduce the adipocyte transcription</td>
<td align="left">
<xref ref-type="bibr" rid="B142">Yang et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="center">Xianlingubao Prescription (XLGB)</td>
<td align="center">Epimedii Folium, Anemarrhenae Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, Psoraleae Fructus, Dipsaci Radix, and Rehmanniae Radix</td>
<td align="center">IL-17, HIF-1, insulin resistance, Th-17 signaling pathway; promote blood circulation</td>
<td align="left">
<xref ref-type="bibr" rid="B168">Zhu and Hou (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Hachimi-jio-gan (HJG)</td>
<td align="center" style="color:#212121">
<italic>Rehmanniae radix, Corni fructus, Dioscoreae rhizome, Alismatis rhizome, Hoelen, Moutan cortex, Cinnamoni cortex, Aconiti tuber</italic>
</td>
<td align="center">Produce qi and increase bone mass</td>
<td align="left">
<xref ref-type="bibr" rid="B2">An et al. (2016),</xref> <xref ref-type="bibr" rid="B92">Qu et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">Erxian decoction (EXD)</td>
<td align="center">Curculigo orchioides Gaertn., Epimedium brevicornu Maxim., Angelica sinensis (Oliv.) Diels, Morinda officinalis F.C. How, Phellodendron chinense C.K. Schneid, and Anemarrhena asphodeloides Bunge</td>
<td align="center">Reduce TNF-&#x3b1;, osteoblast apoptosis, and purge Huo</td>
<td align="left">
<xref ref-type="bibr" rid="B144">Yang et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">Bu Zong Yi Qi Tang</td>
<td align="center">Astragalus membranaceus (Fisch.) Bunge, Atractylodes macrocephala, Citrus reticulata Blanto, Cimicifuga foetida L., Radix Bupleuri, Panax ginseng C. A. Mey., Glycyrrhiza uralensis Fisch., and Angelica sinensis</td>
<td align="center">Enhance BMD and elevate estrogen level in serum</td>
<td align="left">
<xref ref-type="bibr" rid="B98">Sakamoto et al. (2000)</xref>
</td>
</tr>
<tr>
<td align="center">Dang Gui Bu Xue Tang (DBT)</td>
<td align="center">Astragalus membranaceus (Fisch.) Bunge var. mongholicus (Bunge) P. K. Hsiao, Angelica sinensis (Oliv.) Diels</td>
<td align="center">Elevate BMD, MDA, and bone trabecula degradation and increase endogenous SOD activity</td>
<td align="left">
<xref ref-type="bibr" rid="B134">Xie et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="center">Ba Wei Di Huang Wan</td>
<td align="center">(Rhizome), Poria cocos (Schw.) Wolf (Sclerotium, Alisma orientale (Sam.) Juz., Cornus officinalis Sieb. et Zucc, Aconitum carmichaeli Debx., and Cinnamomum cassia Presl</td>
<td align="center">Increase trabecular bone volume and BMD and improve the microstructure of the bone</td>
<td align="left">
<xref ref-type="bibr" rid="B12">Chen et al. (2012b)</xref>
</td>
</tr>
<tr>
<td align="center">Gu Ling Pian (GLP)</td>
<td align="center">Drynaria fortunei (Kunze ex Mett.) J. Sm and Cuscuta chinensis Lam. <italic>Cervus elaphus</italic> Linnaeus</td>
<td align="center">Increase MG-63 cells and regulate the ratio of OPG/RANKL via the p38 MARK pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B166">Zhao et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="center">Bu Shen Ning Xin Decoction (BSNXD)</td>
<td align="center">Rehmannia glutinosa Libosch, Curculigo orchioides Gaertn., Cullen corylifolium (Linnaeus) Medikus, Hominis Placenta, Dioscorea opposita Thunb. Paeonia suffruticosa Andr., Atractylodes macrocephala Koidz., and Lycium barbarum L</td>
<td align="center">Enhance osteoblastic proliferation and inhibit the apoptosis of osteoblasts through the MARK pathway activated by pERK</td>
<td align="left">
<xref ref-type="bibr" rid="B121">Wang et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="center">Wu Jia Bu Gu recipe</td>
<td align="center">Acanthopanax senticosus (Rupr. et Maxim.) Harms, Rehmannia glutinosa Libosch Achyranthes bidentata Bl., Astragalus membranaceus (Fisch.) Bunge var. mongholicus (Bunge)P. K. Hsiao, Angelica sinensis (Oliv.) Diels, and Ostrea gigas Thunberg</td>
<td align="center">Increased ALP, serum Ca, and P, deposition of external calcium, production of collagen I, BMD maximum load, and elastic load, TBV%, TFS%, AFS%, and MAR</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Fu et al. (2010)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s5">
<title>5 Therapeutic mechanism of TCM on anti-osteoporosis</title>
<p>Although TCM has certain advantages in the treatment of osteoporosis, its therapeutic mechanism has not been fully elucidated, which is undoubtedly a huge challenge for researchers. In this study, we summarize and generalize the signaling pathways involved in OP, which may provide a certain theoretical basis for further elucidation of OP treatment with TCM. According to previous studies, Wnt/&#x3b2;-catenin, BMP-SMAD, MAPK, and RANK/NF-&#x3ba;B/OPG play a key role in OP (<xref ref-type="bibr" rid="B117">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="B124">Wei et al., 2022</xref>) (<xref ref-type="table" rid="T3">Table3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Signaling pathways involved in osteoporosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Signaling pathways</th>
<th align="center">Regulator</th>
<th align="center">Mechanism</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="6" align="center">Wnt/&#x3b2;-catenin signaling pathway</td>
<td align="center">Runx2</td>
<td align="center">Directly regulate the expression of Runx2, thereby promoting the transdifferentiation of vascular smooth muscle cells and calcification of osteoblast</td>
<td align="left">
<xref ref-type="bibr" rid="B7">Cai et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">FoxO3</td>
<td align="center">Runx2 could cooperate with FoxO3</td>
<td align="left">
<xref ref-type="bibr" rid="B153">Yuan et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">miR-29a</td>
<td align="center">A downstream factor of Wnt/&#x3b2;-catenin signal transduction, could ameliorate age-induced osteoblast loss and osteoporosis</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Lian et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">TGF&#x3b2;</td>
<td align="center">Induce the secretion of Wnt1, thereby combining bone resorption with bone formation</td>
<td align="left">(Weivoda et al., 2016)</td>
</tr>
<tr>
<td align="center">IGF-1</td>
<td align="center">Antagonized the Wnt/&#x3b2;-catenin signaling pathway by catalyzing the transcription of Axin2 and stabilizing the Axin1 protein</td>
<td align="left">E. (2018), <xref ref-type="bibr" rid="B67">Lindsey and Mohan (2016),</xref> Zhang et al. (2019)</td>
</tr>
<tr>
<td align="center">Glucocorticoid</td>
<td align="center">Can stimulate the differentiation of osteoblasts, thereby inhibiting bone formation through Wnt/&#x3b2;-catenin, BMPs, and other classical pathways</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Compston (2018)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">TGF-&#x3b2;/BMP signaling pathway</td>
<td align="center">Smad2/3</td>
<td align="center">Could be activated by TGF-&#x3b2; and then regulated the TGF-&#x3b2;-induced differentiation of chondrocyte and osteoblast in the Smad-dependent pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Kang et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="center">MAPKs</td>
<td align="center">BMP signals could transduce the signal to the MAPK or Smad signaling pathway, which further regulated the transcription of related genes that are involved in the differentiation of osteoblasts and formation of bone</td>
<td align="left">
<xref ref-type="bibr" rid="B129">Wu et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">Others</td>
<td align="center">BMP-2 can promote osteogenesis by regulating the expression of Runx2, ALP, and integrin-binding sialoprotein and activate osteoclast through the upregulation of TNF-&#x3b1; and NF-&#x3ba;B ligands</td>
<td align="left">
<xref ref-type="bibr" rid="B45">Ingwersen et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">MAPK signaling pathway</td>
<td align="center">ERK1/2</td>
<td align="center">The MAPK pathway was related to osteoclastogenesis as well as bone resorption, and its mechanism may be associated with the phosphorylation of ERK1/2</td>
<td align="left">
<xref ref-type="bibr" rid="B71">Long et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">RUNX2</td>
<td align="center">The expression of MAPK/p38MAPK could be increased by RUNX2, along with the increases of ALP, OCN, and OSX</td>
<td align="left">
<xref ref-type="bibr" rid="B95">Ren et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">AGEs</td>
<td align="center">P38, ERK, and JNK can be activated by AGEs and contribute to the release of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6</td>
<td align="left">
<xref ref-type="bibr" rid="B118">Wang et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">RANKL/NF-&#x3ba;B/OPG signaling pathway</td>
<td align="center">LGR4</td>
<td align="center">Could competitively bind RANKL to RANK and block classical RANK signaling</td>
<td align="left">
<xref ref-type="bibr" rid="B72">Luo et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">TNF</td>
<td align="center">Could regulate the expressions of FoxO1, Sod2, and catalase and accumulation of ROS, which were involved in the activation of the NF-&#x3ba;B pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B65">Liao et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">Glucocorticoids</td>
<td align="center">Contribute to the formation of osteoclast and expressions of RANKL and macrophage colony-stimulating factor (MCSF), inhibit the level of serum OPG, and activate and mature osteoclasts</td>
<td align="left">
<xref ref-type="bibr" rid="B15">Chotiyarnwong and McCloskey (2020)</xref>
</td>
</tr>
<tr>
<td align="left"/>
<td align="center">Estrogen</td>
<td align="center">Could promote the accumulation of superoxide involved in bone remodeling and promote osteogenic differentiation</td>
<td align="left">
<xref ref-type="bibr" rid="B47">Karim et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">PI3K/AKT signaling pathway</td>
<td align="center">Alp, cbfa1, Col1a1, and OCN</td>
<td align="center">The osteoblast-related gene expressions can be upregulated by the phosphorylation levels of PI3K and Akt</td>
<td align="left">
<xref ref-type="bibr" rid="B135">Xie et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">mTOR signaling pathway</td>
<td align="center">Glucocorticoids</td>
<td align="center">Can promote the apoptosis and the autophagy of OB through inhibiting the mammalian target of rapamycin</td>
<td align="left">
<xref ref-type="bibr" rid="B15">Chotiyarnwong and McCloskey (2020)</xref>
</td>
</tr>
<tr>
<td align="center">ER&#x3b1;-AMPK-Sirt1 signaling pathway</td>
<td align="center">LKBl</td>
<td align="center">ER, including ER-&#x3b1; and ER-&#x3b2;, can directly increase the activity of LKBl, which is the most important upstream protein kinase of AMPK; the mutual promotion of AMPK and Sirt1 can also modulate the autophagy or apoptosis of osteoblast</td>
<td align="left">
<xref ref-type="bibr" rid="B132">Xiao et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">JAK-STAT signaling pathway</td>
<td align="center">IGF-I</td>
<td align="center">Growth hormone facilitated longitudinal bone growth primarily via the production of hepatic IGF-I, and growth hormone receptor was activated and then induced the phosphorylation of the JAK-STAT signaling <break/>pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B67">Lindsey and Mohan (2016)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s5-1">
<title>5.1 Wnt/&#x3b2;-catenin signaling pathway</title>
<p>Wnt signaling is a critical signal transduction pathway and mainly regulates embryonic development and tissue regeneration (<xref ref-type="bibr" rid="B81">Nusse and Clevers, 2017</xref>). As a kind of secretory glycoprotein, Wnt-regulating signaling was associated with multiple genes and various receptors, all of which could regulate canonical &#x3b2;-catenin-dependent and non-canonical &#x3b2;-catenin-independent pathways (<xref ref-type="bibr" rid="B122">Wang et al., 2019</xref>). Among them, the canonical Wnt signaling pathway could be regulated at many levels, including negative regulation. During this process, DKK1, a negative regulator, can bind to the LRP receptor, thereby suppressing the Wnt signaling pathway. When cells were not exposed to Wnt signaling, major signaling components, such as &#x3b2;-catenin and receptors, were in a closed state (<xref ref-type="bibr" rid="B80">Nusse, 2012</xref>). When it was at an active state, Wnt signaling could activate the intracellular protein DVL and inhibit the degradation activity of the &#x3b2;-catenin degradation complex formed by GSK-3&#x3b2;. In non-canonical &#x3b2;-catenin-independent signaling pathways, Wnt could induce cytoskeletal re-arrangement through the activation of GTPase, including Rho and Rac (<xref ref-type="bibr" rid="B113">van Amerongen et al., 2008</xref>).</p>
<p>Wnt/&#x3b2;-catenin could regulate bone metabolism by controlling the differentiation and function of mesenchymal stem cells (<xref ref-type="bibr" rid="B169">Zhu et al., 2019</xref>), adipose-derived stem cells (<xref ref-type="bibr" rid="B100">Shao et al., 2017</xref>), osteoblasts, and osteoclasts. The specific mechanism of action was as follows: Runx2, a specific transcription factor, plays a vital role in osteoblast differentiation and chondrocyte maturation (<xref ref-type="bibr" rid="B51">Komori, 2018</xref>). Cai et al. found that Wnt/&#x3b2;-catenin could directly regulate the expression of Runx2, thereby promoting vascular smooth muscle cells to transdifferentiation (<xref ref-type="bibr" rid="B7">Cai et al., 2016</xref>). In addition, Runx2 could cooperate with the forkhead box protein O3 transcription factor (FoxO3) that belongs to a subclass of forkhead transcription factors (<xref ref-type="bibr" rid="B153">Yuan et al., 2022</xref>). Moreover, Runx2 could cross-conduce with the Wnt signal, all of which were involved in the elimination of superoxide, thereby remodeling normal bone. In addition, miR-29a, a downstream factor of Wnt/&#x3b2;-catenin, could ameliorate age-induced osteoblast loss and OP by targeting Dnmt3b-mediated FoxO3 methylation, upregulating the expressions of antioxidant proteins and DNA methylation (<xref ref-type="bibr" rid="B63">Lian et al., 2021</xref>). Similarly, FoxO1 was also involved in the degradation of spontaneous cartilage and the formation of osteoarthritis. Matsuzaki et al. found that the ectopic expression of FoxO1 could synergize with the stimulation of transforming growth factor-&#x3b2; (TGF-&#x3b2;), leading to the differentiation of macrophages along with the release of IL-1&#x3b2; (<xref ref-type="bibr" rid="B74">Matsuzaki et al., 2018</xref>). In addition, TGF-&#x3b2;in osteoclast can induce the secretion of Wnt1, thereby combining bone resorption with bone formation (<xref ref-type="bibr" rid="B125">Weivoda et al., 2016</xref>). Moreover, the paracrine secretion of DKK1 (a Wnt inhibitor) induced by TGF-&#x3b2; is essential for osteoclastogenesis. Subsequently, Esposito found that TGF-&#x3b2; could induce the biomolecular aggregation of DACT1, which suppresses the Wnt signaling pathway and promotes bone metastasis (<xref ref-type="bibr" rid="B26">Esposito et al., 2021</xref>). Furthermore, Zhang et al. found that insulin inhibited autophagy and promoted premature aging through the TGF-&#x3b2; pathway, thus inhibiting BMSC osteogenesis. (<xref ref-type="bibr" rid="B161">Zhang et al., 2020</xref>). IGF could directly affect the differentiation of osteoblasts and enhance the function of mature osteoblasts, thereby promoting the formation of bone collagen and bone matrix (<xref ref-type="bibr" rid="B131">Xian et al., 2012</xref>). During this process, IGF-1 antagonized the Wnt/&#x3b2;-catenin signaling pathway by catalyzing the transcription of Axin2 and stabilizing the Axin1 protein. Meanwhile, the IGF-1 receptor can phosphorylate and degrade &#x3b2;-catenin, activate GSK-3&#x3b2;, and degrade insulin receptor substrate 1, all of which contribute to glucose and bone metabolism (E., 2018; <xref ref-type="bibr" rid="B67">Lindsey and Mohan, 2016</xref>; <xref ref-type="bibr" rid="B154">Zhang B. et al., 2019</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>). Additionally, the physiological dose of glucocorticoid can stimulate the differentiation of osteoblasts, thereby inhibiting bone formation through BMPs and other classical pathways (<xref ref-type="bibr" rid="B16">Compston, 2018</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Role of the Wnt/&#x3b2;-catenin signaling pathway in osteoporosis. Interleukin, IL; insulin-like growth factor-1, IGF-1; lipoprotein receptor-related protein, LRP; disheveled, DVL; glycogen synthase kinase-3&#x3b2;, GSK-3&#x3b2;; DNA methyltransferase 3B, Dnmt3b; runt-related transcription factor 2, Runx2; forkhead box O, FoxO; dickkopf-1, DKK1; disheveled binding antagonist of beta-catenin 1, DACT1; and transforming growth factor-beta, TGF-&#x3b2;.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g003.tif"/>
</fig>
</sec>
<sec id="s5-2">
<title>5.2 TGF-&#x3b2;/BMP signaling pathway</title>
<p>Similar to the role of the Wnt/&#x3b2;-catenin signaling pathway, the TGF-&#x3b2;/BMP signaling pathway also plays a crucial regulatory role in the body, especially in the homeostasis of postnatal bone and differentiation of mesenchymal cells into osteoblasts (<xref ref-type="bibr" rid="B10">Chen G. et al., 2012</xref>; <xref ref-type="bibr" rid="B129">Wu et al., 2016</xref>), which may be due to DNA synthesis and cell replication. Specifically, there are three main forms of TGF-&#x3b2; in mammals: TGF-&#x3b2;1, TGF-&#x3b2;2, and TGF-&#x3b2;3 (<xref ref-type="bibr" rid="B21">Derynck and Erine, 2019</xref>), all of which could be activated and bind to TGF-&#x3b2; I receptors (T&#x3b2;RI) and two type II receptors (T&#x3b2;RII). Subsequently, TGF-&#x3b2; could transmit its signals to the Smad signaling pathway both in canonical-dependent and non-canonical-independent forms (<xref ref-type="bibr" rid="B129">Wu et al., 2016</xref>). For example, Smad2/3 could be activated by TGF-&#x3b2;, regulating the TGF-&#x3b2;-induced differentiation of chondrocyte and osteoblast through the Smad pathway. Moreover, Smad2/3 also recruited HDACs 4/5 and inhibited Runx2 function, all of which could participate in osteoblast differentiation (<xref ref-type="bibr" rid="B46">Kang et al., 2005</xref>), while in the Smad-independent pathway, TGF-&#x3b2; accelerates the proliferation and differentiation of osteoblast by regulating MAPK and Smad2/3 signaling pathways (<xref ref-type="bibr" rid="B73">Matsunobu et al., 2009</xref>). In addition, MAPK could positively regulate the function of Runx2, contributing to the differentiation of MSCs (<xref ref-type="bibr" rid="B59">Li et al., 2009</xref>).</p>
<p>In bone, BMP signals were also mediated by their receptors and formed complex bodies with them, further regulating the transcription of related genes involved in the differentiation of osteoblast and formation of bone (<xref ref-type="bibr" rid="B129">Wu et al., 2016</xref>). Among BMPs, BMP-2 could promote osteogenesis by regulating the expression of Runx2, ALP, and integrin-binding sialoprotein and activate osteoclast through the upregulation of TNF-&#x3b1; and NF-&#x3ba;B ligands (<xref ref-type="bibr" rid="B45">Ingwersen et al., 2022</xref>). Moreover, BMP/Smad1 could regulate the activity of atonal homolog 8 and inhibit the expression ratio of RANKL/OPG, thereby regulating the osteoclast number negatively and promoting bone resorption and loss (<xref ref-type="bibr" rid="B139">Yahiro et al., 2020</xref>) (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Role of the TGF-&#x3b2;/BMP signaling pathway in osteoporosis. Transforming growth factor-beta, TGF-&#x3b2;; TGF-&#x3b2; type I receptor, T&#x3b2;R; runt-related transcription factor 2, Runx2; histone deacetylases, HDACs; mitogen-activated protein kinase, MAPK; bone morphogenetic protein, BMP; tumor necrosis factor-&#x3b1;, TNF-&#x3b1;; and nuclear factor-&#x3ba;B, NF-&#x3ba;B.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g004.tif"/>
</fig>
</sec>
<sec id="s5-3">
<title>5.3 MAPK signaling pathway</title>
<p>MAPK is a class of conserved serine/threonine protein kinases and plays a role in cell proliferation, differentiation, and apoptosis (<xref ref-type="bibr" rid="B164">Zhang W, 2003</xref>). In mammals, three families of MAPK have been identified: JNK kinase, extracellular signal-regulated protein kinase (ERK), and p38 MAPK. Among these, the MAPK-mediated pathway is within an enzymatic cascade, which comprises at least three continuously activated enzymes (<xref ref-type="bibr" rid="B127">Widmann et al., 1999</xref>).</p>
<p>In OP, the MAPK pathway was related to the osteoclastogenesis as well as bone resorption, which was due to its role in the phosphorylation of ERK1/2 that could, in sequence, regulate the transcription and expression of the main osteoclast transcription factor, such as a recombinant nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) (<xref ref-type="bibr" rid="B71">Long et al., 2022</xref>). In addition, Ren et al. found that the expression of MAPK/p38MAPK could be increased by RUNX2, along with the increases of ALP, OCN, and OSX, all of which were associated with the osteoblast differentiation and downregulation of autophagy genes, including Beclin-1, ATG1, and p62 (<xref ref-type="bibr" rid="B95">Ren et al., 2022</xref>). In addition, the MAPK signaling pathway also takes part in high-glucose-caused osteoclast differentiation, which was associated with Dickkopf-1 and tartrate-resistant acid phosphatase 5B (TRAP5b), c-terminal telopeptides of type 1 (CTX1), cathepsin K, and Nqo1 (<xref ref-type="bibr" rid="B95">Ren et al., 2022</xref>). Moreover, downstream of MAPK, pathways such as P38, ERK, and JNK can be activated by AGEs and contribute to the release of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 (<xref ref-type="bibr" rid="B118">Wang et al., 2020</xref>) (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Role of the MAPK signaling pathway in osteoporosis. Advanced glycation end products, AGEs; runt-related transcription factor 2, Runx2; SAPK/Erk kinase 1, SEK1; Jun N-terminal kinase, JNK; mitogen-activated protein kinase kinase, MEK; mitogen-activated protein kinase kinase kinase, MEKK1; extracellular signal-regulated kinases, ERK; transforming growth factor-&#x3b2;-activated kinase 1, TAK1; MAP kinase kinase-3, MKK3; C-terminal telopeptide of type I collagen, CTX1; tartrate-resistant acid phosphatase isoform 5b, TRAP5b; dickkopf-1, Dkk1; anti-human t-lymphocyte globulin 1, ATG1; nuclear factor of activated T-cells 1, NFATC1; and interleukin, IL.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g005.tif"/>
</fig>
</sec>
<sec id="s5-4">
<title>5.4 RANKL/NF-&#x3ba;B/OPG signaling pathway</title>
<p>The RANKL/NF-kB/OPG pathway, mainly involved in osteoclast formation (<xref ref-type="bibr" rid="B126">Whyte, 2006</xref>), is a process initiated by the binding of RANKL to RANK (<xref ref-type="bibr" rid="B145">Yang W. et al., 2021</xref>). RNAKL, known as TNF superfamily member 11 (TNFSF11), mainly regulates the differentiation of osteoclasts and the formation of OP (<xref ref-type="bibr" rid="B72">Luo et al., 2016</xref>). During osteoclast differentiation, leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4) (a receptor of RANKL) could competitively bind RANKL to RANK and block classical RANK way, along with activations of the glycogen synthase kinase-3 (GSK3)-&#x3b2;, &#x3b1; subunit of inhibitory G protein (G&#x3b1;q), and NFATC1 (<xref ref-type="bibr" rid="B72">Luo et al., 2016</xref>). In addition, TNF could regulate the activation of the NF-&#x3ba;B pathway through the expressions of FoxO1, Sod2, and catalase and accumulation of ROS (<xref ref-type="bibr" rid="B65">Liao et al., 2016</xref>); under normal conditions, NF-&#x3ba;B can form a dimer with I&#x3ba;B&#x3b1; in the cytoplasm; upon stimulation, the dimer was dissociated, along with NF-&#x3ba;B entering the nucleus and I&#x3ba;B&#x3b1; phosphorylation, resulting in the synthesis and release of inflammatory factors, all of which promoted osteoclast formation, osteoclast differentiation, and osteolysis (<xref ref-type="bibr" rid="B171">Zou et al., 2020</xref>). Additionally, long-term use or overdose of glucocorticoids contribute to the formation of osteoclast and expressions of RANKL and macrophage colony-stimulating factor (MCSF), inhibiting the level of serum OPG and activating osteoclasts (<xref ref-type="bibr" rid="B15">Chotiyarnwong and McCloskey, 2020</xref>). Moreover, estrogen could promote the accumulation of superoxide involved in bone remodeling and promote osteogenic differentiation. In postmenopausal osteoporosis, deficiency of estrogen led to unbalanced bone homeostasis, a decrease in OPG expression, and increases in RANKL and M-CSF (<xref ref-type="bibr" rid="B47">Karim et al., 2021</xref>) (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Role of the RANK/NF-&#x3ba;B (RANKL)/OPG signaling pathway in osteoporosis. Nuclear factor-&#x3ba;B, NF-&#x3ba;B; nuclear factor kappa B, RANK; nuclear factor-&#x3ba;B ligand, RANKL; inhibitor of NF-&#x3ba;B &#x3b1;, I&#x3ba;B&#x3b1;; osteoprotegerin, OPG; interleukin, IL; glycogen synthase kinase-3&#x3b2;, GSK-3&#x3b2;; nuclear factor of activated T-cells 1, NFATC1; forkhead box O, FoxO; reactive oxygen species, ROS; and macrophage colony-stimulating factor, MCSF.</p>
</caption>
<graphic xlink:href="fphar-15-1370900-g006.tif"/>
</fig>
</sec>
<sec id="s5-5">
<title>5.5 Other pathways related to the pathogenesis of osteoporosis</title>
<p>In addition to the above signal paths, relevant research showed that PI3K/AKT/mTOR, ER&#x3b1;-AMPK, GH/IGF (<xref ref-type="bibr" rid="B67">Lindsey and Mohan, 2016</xref>), and calcium signaling pathways also participate in OP pathogenesis. The osteoblast-related gene expressions, including Alp, cbfa1, Col1a1, and osteocalcin (OCN), can be upregulated by the phosphorylation of PI3K and Akt (<xref ref-type="bibr" rid="B135">Xie et al., 2022</xref>). Low levels of glucocorticoids can promote the apoptosis and autophagy of OB through inhibiting the mammalian target of rapamycin (mTOR) pathway (<xref ref-type="bibr" rid="B15">Chotiyarnwong and McCloskey, 2020</xref>). ER, including ER-&#x3b1; and ER-&#x3b2;, can directly increase the activity of LKBl, which is the most important upstream protein kinase of AMPK. In addition, the mutual promotion of AMPK and Sirt1 can also modulate the autophagy or apoptosis of osteoblasts, suggesting that the ER&#x3b1;-AMPK-Sirt1 signaling pathway may play an important role in OP (<xref ref-type="bibr" rid="B132">Xiao et al., 2022</xref>). Furthermore, growth hormone facilitated longitudinal bone growth primarily via the production of hepatic IGF-I, and the growth hormone receptor was activated and then induced the phosphorylation of the Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway (<xref ref-type="bibr" rid="B67">Lindsey and Mohan, 2016</xref>). Of note, the JAK-STAT pathway can disrupt normal bone remodeling by targeting osteoclasts and osteoblasts in the joint and in the joint exoskeleton (<xref ref-type="bibr" rid="B20">Damerau et al., 2020</xref>).</p>
</sec>
</sec>
<sec id="s6">
<title>6 Clinical or preclinical studies of TCM in OP treatment</title>
<p>TCM has unique advantages in the treatment of osteoporosis, which mainly lies in the overall regulation of the balance of yin and yang of the human body (<xref ref-type="bibr" rid="B40">Hu et al., 2019</xref>), fundamentally improving bone metabolism and repair, and preventing and treating the occurrence and development of OP from various aspects (<xref ref-type="bibr" rid="B89">Qian et al., 2021</xref>). As we mentioned, TCM has made certain progress in the treatment of OP, which is not only reflected in preclinical research but has also achieved good results in clinical research. At present, the National Medical Products Administration has approved many Chinese patent drugs for the treatment of OP in China. Among them, the Xianling Gubao capsule (tablet) (<xref ref-type="bibr" rid="B133">Xiao et al., 2022</xref>), Gushukang capsule (granule) (<xref ref-type="bibr" rid="B61">Li et al., 2022</xref>), Jintiange capsule (<xref ref-type="bibr" rid="B64">Liang et al., 2022</xref>), and Qianggu capsule (<xref ref-type="bibr" rid="B42">Huang et al., 2022</xref>) are more widely used. In addition, the characteristic therapy of OP in Chinese medicine includes acupuncture, moxibustion, treatment by way of pasting on acupuncture points, massage, and so on (<xref ref-type="bibr" rid="B86">Peng Z. et al., 2022</xref>). To sum up, there are various methods for the treatment of OP by TCM, but it is worth noting that appropriate therapies should be selected according to different syndrome types under the guidance of the TCM theory.</p>
</sec>
<sec id="s7">
<title>7 Conclusion and future prospects</title>
<p>The pathogenic factors and related pathways in OP reported in this review provide a basis for better elucidating the pathogenesis of osteoporosis. TCM, including syndrome differentiation, single herbs, and prescription, shows a unique advantage in the treatment of osteoporosis, which undoubtedly points out the direction for researchers. However, besides the abovementioned diseases related to osteoporosis, whether there are other diseases that can affect OP or not needs to be studied.</p>
<p>Although TCM has certain advantages in the treatment of osteoporosis, the material basis is unclear, which brings challenges to clinical application. Compared with the single target of chemical drugs, the multi-pathway and multi-target characteristics of TCM are not only advantages but also disadvantages, which is also a major challenge for the internationalization of TCM. This review summarizes the potential of TCM in the treatment of osteoporosis, but its specific mechanism is worth further research. The solution to this problem will be beneficial to the long-term development of TCM in the treatment of osteoporosis.</p>
</sec>
</body>
<back>
<sec id="s8">
<title>Author contributions</title>
<p>GC: writing&#x2013;original draft. SH: writing&#x2013;original draft. YN: writing&#x2013;original draft. XD: writing&#x2013;review and editing. CD: writing&#x2013;review and editing. LW: writing&#x2013;review and editing. ZW: writing&#x2013;review and editing. XS: writing&#x2013;review and editing. QY: writing&#x2013;review and editing. JS: writing&#x2013;review and editing. MH: writing&#x2013;review and editing. XH: writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The authors declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amarasekara</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rho</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Bone loss triggered by the cytokine network in inflammatory autoimmune diseases</article-title>. <source>J. Immunol. Res.</source> <volume>2015</volume>, <fpage>832127</fpage>. <pub-id pub-id-type="doi">10.1155/2015/832127</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Natural products for treatment of osteoporosis: the effects and mechanisms on promoting osteoblast-mediated bone formation</article-title>. <source>Life Sci.</source> <volume>147</volume>, <fpage>46</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2016.01.024</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bazzocchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Celi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lauro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sorge</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tarantino</surname>
<given-names>U.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Relationship between body composition, body mass index and bone mineral density in a large population of normal, osteopenic and osteoporotic women</article-title>. <source>Radiol. Med.</source> <volume>116</volume>, <fpage>1115</fpage>&#x2013;<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1007/s11547-011-0689-2</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kansagara</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lazur</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harrod</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American college of physicians</article-title>. <source>Ann. Intern Med.</source> <volume>176</volume>, <fpage>182</fpage>&#x2013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.7326/M22-0684</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett-Connor</surname>
<given-names>E. H. T.</given-names>
</name>
<name>
<surname>Holbrook</surname>
<given-names>T. L.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus</article-title>. <source>JAMA</source> <volume>268</volume>, <fpage>3333</fpage>&#x2013;<lpage>3337</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1992.03490230063029</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellavia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dimarco</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Carina</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raimondi</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Flavonoids in bone erosive diseases: perspectives in osteoporosis treatment</article-title>. <source>Trends Endocrinol. Metab.</source> <volume>32</volume>, <fpage>76</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2020.11.007</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>WNT/&#x3b2;-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression</article-title>. <source>Exp. Cell Res.</source> <volume>345</volume>, <fpage>206</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2016.06.007</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>X.-y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.-j.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>J.-l.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.-t.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Experimental and molecular docking studies of estrogen-like and anti-osteoporosis activity of compounds in Fructus Psoraleae</article-title>. <source>J. Ethnopharmacol.</source> <volume>276</volume>, <fpage>114044</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114044</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Ziadlou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Effect and mechanism of psoralidin on promoting osteogenesis and inhibiting adipogenesis</article-title>. <source>Phytomedicine</source> <volume>61</volume>, <fpage>152860</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2019.152860</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. P.</given-names>
</name>
</person-group> (<year>2012a</year>). <article-title>TGF-&#x3b2; and BMP signaling in osteoblast differentiation and bone formation</article-title>. <source>Int. J. Biol. Sci.</source> <volume>8</volume>, <fpage>272</fpage>&#x2013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.2929</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>L. U.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/&#x3b2;-catenin pathway</article-title>. <source>Exp. Ther. Med.</source> <volume>12</volume>, <fpage>279</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2016.3333</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2012b</year>). <article-title>Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats</article-title>. <source>J. Ethnopharmacol.</source> <volume>142</volume>, <fpage>80</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2012.04.017</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Chien-Fu Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Chiou</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Protective effects and network analysis of natural compounds obtained from Radix dipsaci, Eucommiae cortex, and Rhizoma drynariae against RANKL-induced osteoclastogenesis <italic>in vitro</italic>
</article-title>. <source>J. Ethnopharmacol.</source> <volume>244</volume>, <fpage>112074</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112074</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chesnut</surname>
<given-names>C. H.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Silverman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andriano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Genant</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gimona</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group</article-title>. <source>Am. J. Med.</source> <volume>109</volume>, <fpage>267</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9343(00)00490-3</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chotiyarnwong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>McCloskey</surname>
<given-names>E. V.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment</article-title>. <source>Nat. Rev. Endocrinol.</source> <volume>16</volume>, <fpage>437</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1038/s41574-020-0341-0</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Compston</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Glucocorticoid-induced osteoporosis: an update</article-title>. <source>Endocrine</source> <volume>61</volume>, <fpage>7</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s12020-018-1588-2</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Compston</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>McClung</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>W. D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Osteoporosis</article-title>. <source>Lancet</source> <volume>393</volume>, <fpage>364</fpage>&#x2013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32112-3</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Silverman</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Lewiecki</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>A systematic review of persistence and compliance with bisphosphonates for osteoporosis</article-title>. <source>Osteoporos. Int.</source> <volume>18</volume>, <fpage>1023</fpage>&#x2013;<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.1007/s00198-006-0322-8</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease</article-title>. <source>Spine (Phila Pa 1976)</source> <volume>35</volume>, <fpage>2121</fpage>&#x2013;<lpage>2127</lpage>. <pub-id pub-id-type="doi">10.1097/BRS.0b013e3181edfd17</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damerau</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gaber</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohrndorf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>JAK/STAT activation: a general mechanism for bone development, homeostasis, and regeneration</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>9004</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21239004</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derynck</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Erine</surname>
<given-names>H. B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Specificity, versatility, and control of TGF-&#x3b2; family signaling</article-title>. <source>Sci. Signal</source> <volume>12</volume>, <fpage>eaav5183</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.aav5183</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eastell</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>O&#x27;Neill</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Hofbauer</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Langdahl</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>I. R.</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>D. T.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Postmenopausal osteoporosis</article-title>. <source>Nat. Rev. Dis. Prim.</source> <volume>2</volume>, <fpage>16069</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.69</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eastell</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Szulc</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Use of bone turnover markers in postmenopausal osteoporosis</article-title>. <source>Lancet Diabetes Endocrinol.</source> <volume>5</volume>, <fpage>908</fpage>&#x2013;<lpage>923</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(17)30184-5</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Gazzar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>H&#xf6;gler</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>625</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22020625</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ernesto</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Management of endocrine disease: novel anabolic treatments for osteoporosis</article-title>. <source>Eur. J. Endocrinol.</source> <volume>178</volume>, <fpage>R33</fpage>&#x2013;<lpage>R44</lpage>. <pub-id pub-id-type="doi">10.1530/eje-17-0920</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Spadazzi</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>TGF-&#x3b2;-induced DACT1 biomolecular condensates repress Wnt signalling to promote bone metastasis</article-title>. <source>Nat. Cell Biol.</source> <volume>23</volume>, <fpage>257</fpage>&#x2013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1038/s41556-021-00641-w</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A promising biomarker of elevated galanin level in hypothalamus for osteoporosis risk in type 2 diabetes mellitus</article-title>. <source>Mech. Ageing Dev.</source> <volume>194</volume>, <fpage>111427</fpage>. <pub-id pub-id-type="doi">10.1016/j.mad.2020.111427</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsblad D&#x27;Elia</surname>
<given-names>H. L. A.</given-names>
</name>
<name>
<surname>Waltbrand</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kvist</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mellstr&#xf6;m</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Saxne</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohlsson</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis</article-title>. <source>Ann. Rheum. Dis.</source> <volume>62</volume>, <fpage>617</fpage>&#x2013;<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1136/ard.62.7.617</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Comparison of effects of Wujia Bugu decoction and alendronate sodium on protection the bone loss of hindlimb unloaded rats</article-title>. <source>Zhongguo gu shang &#x3d; China J. Orthop. traumatology</source> <volume>23</volume>, <fpage>524</fpage>&#x2013;<lpage>528</lpage>.</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Yin and Yang of traditional Chinese and western medicine</article-title>. <source>Med. Res. Rev.</source> <volume>41</volume>, <fpage>3182</fpage>&#x2013;<lpage>3200</lpage>. <pub-id pub-id-type="doi">10.1002/med.21793</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Network pharmacology-based pharmacological mechanism of the Chinese medicine rhizoma drynariae against osteoporosis</article-title>. <source>Med. Sci. Monit.</source> <volume>25</volume>, <fpage>5700</fpage>&#x2013;<lpage>5716</lpage>. <pub-id pub-id-type="doi">10.12659/MSM.915170</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ge</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Protective effects of naringin on glucocorticoid-induced osteoporosis through regulating the PI3K/Akt/mTOR signaling pathway</article-title>. <source>Am. J. Transl. Res.</source> <volume>13</volume>, <fpage>6330</fpage>&#x2013;<lpage>6341</lpage>.</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gennari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Merlotti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Falchetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eller Vainicher</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cosso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chiodini</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Emerging therapeutic targets for osteoporosis</article-title>. <source>Expert Opin. Ther. Targets</source> <volume>24</volume>, <fpage>115</fpage>&#x2013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1080/14728222.2020.1726889</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Rehmannia glutinosa Libosch extracts prevent bone loss and architectural deterioration and enhance osteoblastic bone formation by regulating the IGF-1/PI3K/mTOR pathway in streptozotocin-induced diabetic rats</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>, <fpage>3964</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20163964</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Elvy Suhana</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The aqueous extract of Eucommia leaves promotes proliferation, differentiation, and mineralization of osteoblast-like mc3t3-E1 cells</article-title>. <source>Evidence-Based Complementary Altern. Med.</source> <volume>2021</volume>, <fpage>3641317</fpage>. <pub-id pub-id-type="doi">10.1155/2021/3641317</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Salvia miltiorrhiza: an ancient Chinese herbal medicine as a source for anti-osteoporotic drugs</article-title>. <source>J. Ethnopharmacol.</source> <volume>155</volume>, <fpage>1401</fpage>&#x2013;<lpage>1416</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2014.07.058</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Qing`e Pill Inhibits Osteoblast Ferroptosis via ATM Serine/Threonine Kinase (ATM) and the PI3K/AKT Pathway in Primary Osteoporosis</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>902102</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.902102</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dagher</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>How the innate immune system senses trouble and causes trouble</article-title>. <source>Clin. J. Am. Soc. Nephrol.</source> <volume>10</volume>, <fpage>1459</fpage>&#x2013;<lpage>1469</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.04680514</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Therapeutic anabolic and anticatabolic benefits of natural Chinese medicines for the treatment of osteoporosis</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1344</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01344</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>End-to-End syndrome differentiation of Yin deficiency and Yang deficiency in traditional Chinese medicine</article-title>. <source>Comput. Methods Programs Biomed.</source> <volume>174</volume>, <fpage>9</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmpb.2018.10.011</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hua</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effects of Achyranthes bidentata alcohol on proliferation capacity of osteoblasts and miRNA in Runx2</article-title>. <source>Exp. Ther. Med.</source> <volume>18</volume>, <fpage>1545</fpage>&#x2013;<lpage>1550</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2019.7723</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Identification of kaempferol as an OSX upregulator by network pharmacology-based analysis of qianggu Capsule for osteoporosis</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>1011561</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1011561</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Icariin alleviates glucocorticoid-induced osteoporosis through EphB4/ephrin-B2 Axis</article-title>. <source>Evid. Based Complement. Altern. Med.</source> <volume>2020</volume>, <fpage>2982480</fpage>. <pub-id pub-id-type="doi">10.1155/2020/2982480</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikebuchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Honma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugamori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Coupling of bone resorption and formation by RANKL reverse signalling</article-title>. <source>Nature</source> <volume>561</volume>, <fpage>195</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-018-0482-7</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingwersen</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naujokat</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Loger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jonitz-Heincke</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>BMP-2 long-term stimulation of human pre-osteoblasts induces osteogenic differentiation and promotes transdifferentiation and bone remodeling processes</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>3077</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23063077</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Alliston</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Delston</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Derynck</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3</article-title>. <source>EMBO J.</source> <volume>24</volume>, <fpage>2543</fpage>&#x2013;<lpage>2555</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7600729</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Giribabu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Salleh</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Marantodes pumilum Var Alata (Kacip Fatimah) ameliorates derangement in RANK/RANKL/OPG pathway and reduces inflammation and oxidative stress in the bone of estrogen-deficient female rats with type-2 diabetes</article-title>. <source>Phytomedicine</source> <volume>91</volume>, <fpage>153677</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2021.153677</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufman</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Management of osteoporosis in older men</article-title>. <source>Aging Clin. Exp. Res.</source> <volume>33</volume>, <fpage>1439</fpage>&#x2013;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1007/s40520-021-01845-8</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khosla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hofbauer</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Osteoporosis treatment: recent developments and ongoing challenges</article-title>. <source>Lancet Diabetes and Endocrinol.</source> <volume>5</volume>, <fpage>898</fpage>&#x2013;<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(17)30188-2</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaus</surname>
<given-names>J. A. G.</given-names>
</name>
<name>
<surname>Steinkamp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Br&#xfc;ckel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rieber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Reinshagen</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>High prevalence of osteoporotic vertebral fractures in patients with Crohn&#x27;s disease</article-title>. <source>Gut</source> <volume>51</volume>, <fpage>654</fpage>&#x2013;<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1136/gut.51.5.654</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komori</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Runx2, an inducer of osteoblast and chondrocyte differentiation</article-title>. <source>Histochem Cell Biol.</source> <volume>149</volume>, <fpage>313</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1007/s00418-018-1640-6</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>N. E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Epidemiology, etiology, and diagnosis of osteoporosis</article-title>. <source>Am. J. Obstet. Gynecol.</source> <volume>194</volume>, <fpage>S3</fpage>&#x2013;<lpage>S11</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2005.08.047</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecka-Czernik</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Diabetes, bone and glucose-lowering agents: basic biology</article-title>. <source>Diabetologia</source> <volume>60</volume>, <fpage>1163</fpage>&#x2013;<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-017-4269-4</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.-N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>C. S.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK</article-title>. <source>J. Bone Mineral Res.</source> <volume>23</volume>, <fpage>1227</fpage>&#x2013;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.1359/jbmr.080325</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H. G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Analyses of the relationship between hyperuricemia and osteoporosis</article-title>. <source>Sci. Rep.</source> <volume>11</volume>, <fpage>12080</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-91570-z</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>M. K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Anti-osteoporotic effects of Salvia miltiorrhiza Bunge EtOH extract both in ovariectomized and naturally menopausal mouse models</article-title>. <source>J. Ethnopharmacol.</source> <volume>258</volume>, <fpage>112874</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.112874</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Inhibition of osteoclast differentiation by tanshinones from the root of Salvia miltiorrhiza bunge</article-title>. <source>Archives pharmacal Res.</source> <volume>28</volume>, <fpage>909</fpage>&#x2013;<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1007/BF02973876</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function</article-title>. <source>Biomed. Pharmacother.</source> <volume>171</volume>, <fpage>116166</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.116166</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>p38 MAPK mediated in compressive stress-induced chondrogenesis of rat bone marrow MSCs in 3D alginate scaffolds</article-title>. <source>J. Cell Physiol.</source> <volume>221</volume>, <fpage>609</fpage>&#x2013;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.21890</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.-S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>P.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.-F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeting the wnt/&#x3b2;-catenin signaling pathway as a potential therapeutic strategy in renal tubulointerstitial fibrosis</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>719880</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.719880</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.-L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.-X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.-F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A clinical herbal prescription Gu-Shu-Kang capsule exerted beneficial effects on the musculoskeletal system of dexamethasone-treated mice by acting on tissue IGF-1 signalling pathway</article-title>. <source>Pharm. Biol.</source> <volume>60</volume>, <fpage>2098</fpage>&#x2013;<lpage>2109</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2022.2132029</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The antiosteoporosis effects of yishen Bugu Ye based on its regulation on the differentiation of osteoblast and osteoclast</article-title>. <source>Biomed. Res. Int.</source> <volume>2020</volume>, <fpage>9467683</fpage>. <pub-id pub-id-type="doi">10.1155/2020/9467683</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Jahr</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MicroRNA-29a mitigates osteoblast senescence and counteracts bone loss through oxidation resistance-1 control of FoxO3 methylation</article-title>. <source>Antioxidants (Basel)</source> <volume>10</volume>, <fpage>1248</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10081248</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: a randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial</article-title>. <source>J. Orthop. Transl.</source> <volume>35</volume>, <fpage>53</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.jot.2022.05.002</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>TNF-&#x391; inhibits FoxO1 by upregulating miR-705 to aggravate oxidative damage in bone marrow-derived mesenchymal stem cells during osteoporosis</article-title>. <source>Stem Cells</source> <volume>34</volume>, <fpage>1054</fpage>&#x2013;<lpage>1067</lpage>. <pub-id pub-id-type="doi">10.1002/stem.2274</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Panayi</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Polydatin ameliorates osteoporosis via suppression of the mitogen-activated protein kinase signaling pathway</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>9</volume>, <fpage>730362</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.730362</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsey</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Mohan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Skeletal effects of growth hormone and insulin-like growth factor-I therapy</article-title>. <source>Mol. Cell. Endocrinol.</source> <volume>432</volume>, <fpage>44</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2015.09.017</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nandakumar</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Asperosaponin VI protects against bone destructions in collagen induced arthritis by inhibiting osteoclastogenesis</article-title>. <source>Phytomedicine</source> <volume>63</volume>, <fpage>153006</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2019.153006</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Uncovering the key miRNAs and targets of the liuwei Dihuang pill in diabetic nephropathy-related osteoporosis based on weighted gene Co-expression network and network pharmacology analysis</article-title>. <source>Endocr. Metab. Immune Disord. Drug Targets</source> <volume>22</volume>, <fpage>274</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.2174/1871530321666210215161921</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Vester-Andersen</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Bendtsen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vind</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Burisch</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 Years of follow-up</article-title>. <source>J. Crohns Colitis</source> <volume>14</volume>, <fpage>904</fpage>&#x2013;<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa019</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Epoxymicheliolide inhibits osteoclastogenesis and resists OVX-induced osteoporosis by suppressing ERK1/2 and NFATc1 signaling</article-title>. <source>Int. Immunopharmacol.</source> <volume>107</volume>, <fpage>108632</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2022.108632</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption</article-title>. <source>Nat. Med.</source> <volume>22</volume>, <fpage>539</fpage>&#x2013;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4076</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsunobu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Torigoe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Vega</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development</article-title>. <source>Dev. Biol.</source> <volume>332</volume>, <fpage>325</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2009.06.002</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuzaki</surname>
<given-names>A.-G. O.</given-names>
</name>
<name>
<surname>Mokuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nagira</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Olmer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gamini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>FoxO transcription factors modulate autophagy and proteoglycan 4 in cartilage homeostasis and osteoarthritis</article-title>. <source>Sci. Transl. Med.</source> <volume>10</volume>, <fpage>eaan0746</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aan0746</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals</article-title>. <source>Braz. J. Med. Biol. Res.</source> <volume>52</volume>, <fpage>e8754</fpage>. <pub-id pub-id-type="doi">10.1590/1414-431X20198754</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammad</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Razaly</surname>
<given-names>N. I.</given-names>
</name>
<name>
<surname>Mohd Rani</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Mohd Aris</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Mohd Effendy</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>An evidence-based review: the effects of Malaysian traditional herbs on osteoporotic rat models</article-title>. <source>Malays. J. Med. Sci.</source> <volume>25</volume>, <fpage>6</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.21315/mjms2018.25.4.2</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akhavan</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Mullins</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Arjmandi</surname>
<given-names>B. H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Macrophage polarization and osteoporosis: a review</article-title>. <source>Nutrients</source> <volume>12</volume>, <fpage>2999</fpage>. <pub-id pub-id-type="doi">10.3390/nu12102999</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Argente</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances</article-title>. <source>Eur. J. Endocrinol.</source> <volume>147</volume>, <fpage>275</fpage>&#x2013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1530/eje.0.1470275</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noh</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Molecular mechanisms and emerging therapeutics for osteoporosis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>7623</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21207623</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Wnt signaling</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>4</volume>, <fpage>a011163</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a011163</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Wnt/&#x3b2;-Catenin signaling, disease, and emerging therapeutic modalities</article-title>. <source>Cell</source> <volume>169</volume>, <fpage>985</fpage>&#x2013;<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagnotti</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Styner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Uzer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Ness</surname>
<given-names>K. K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity</article-title>. <source>Nat. Rev. Endocrinol.</source> <volume>15</volume>, <fpage>339</fpage>&#x2013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1038/s41574-019-0170-1</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>17</volume>, <fpage>545</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-017-2047-y</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paschou</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Dede</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Anagnostis</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Vryonidou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morganstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Goulis</surname>
<given-names>D. G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Type 2 diabetes and osteoporosis: a guide to optimal management</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <volume>102</volume>, <fpage>3621</fpage>&#x2013;<lpage>3634</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2017-00042</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Dharini</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J.-T.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Gu Sui Bu (Drynaria fortunei J. Sm.) antagonizes glucocorticoid-induced mineralization reduction in zebrafish larvae by modulating the activity of osteoblasts and osteoclasts</article-title>. <source>J. Ethnopharmacol.</source> <volume>297</volume>, <fpage>115565</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115565</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Role of traditional Chinese medicine in bone regeneration and osteoporosis</article-title>. <source>Front. Bioeng. Biotechnol.</source> <volume>10</volume>, <fpage>911326</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2022.911326</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponzetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rucci</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Updates on osteoimmunology: what&#x27;s new on the cross-talk between bone and immune system</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>10</volume>, <fpage>236</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2019.00236</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qadir</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Senile osteoporosis: the involvement of differentiation and senescence of bone marrow stromal cells</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>349</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21010349</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O&#x27;Brien</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A traditional Chinese medicine plant extract prevents alcohol-induced osteopenia</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>754088</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.754088</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Aqueous extract of salvia miltiorrhiza bunge-radix Puerariae herb pair attenuates osteoporosis in ovariectomized rats through suppressing osteoclast differentiation</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>581049</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.581049</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Prediction of the mechanisms of action of Shenkang in chronic kidney disease: a network pharmacology study and experimental validation</article-title>. <source>J. Ethnopharmacol.</source> <volume>246</volume>, <fpage>112128</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112128</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kuramasu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagahori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hirayanagi</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Co-administration of the traditional medicines hachimi-jio-Gan and hochu-ekki-to can reverse busulfan-induced aspermatogenesis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>1716</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21051716</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ragipoglu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dudeck</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haffner-Luntzer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kroner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ignatius</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The role of mast cells in bone metabolism and bone disorders</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>163</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00163</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathinavelu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guidry-Elizondo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Banu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Molecular modulation of osteoblasts and osteoclasts in type 2 diabetes</article-title>. <source>J. Diabetes Res.</source> <volume>2018</volume>, <fpage>6354787</fpage>. <pub-id pub-id-type="doi">10.1155/2018/6354787</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Effects of runt-related transcription factor 2 (RUNX2) on the autophagy of rapamycin-treated osteoblasts</article-title>. <source>Bioengineered</source> <volume>13</volume>, <fpage>5262</fpage>&#x2013;<lpage>5276</lpage>. <pub-id pub-id-type="doi">10.1080/21655979.2022.2037881</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robert</surname>
<given-names>S. W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Clinical practice. Glucocorticoid-induced bone disease</article-title>. <source>N. Engl. J. Med.</source> <volume>365</volume>, <fpage>62</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMcp1012926</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossouw</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>LaCroix</surname>
<given-names>A. Z.</given-names>
</name>
<name>
<surname>Kooperberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stefanick</surname>
<given-names>M. L.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women&#x27;s Health Initiative randomized controlled trial</article-title>. <source>JAMA</source> <volume>288</volume>, <fpage>321</fpage>&#x2013;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1001/jama.288.3.321</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sassa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mitamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shinoda</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Preventive effects of a herbal medicine on bone loss in rats treated with a GnRH agonist</article-title>. <source>Eur. J. Endocrinol.</source> <volume>143</volume>, <fpage>139</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1530/eje.0.1430139</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samakkarnthai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sfeir</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Atkinson</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Achenbach</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Wennberg</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Dyck</surname>
<given-names>P. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Determinants of bone material strength and cortical porosity in patients with type 2 diabetes mellitus</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <volume>105</volume>, <fpage>e3718</fpage>&#x2013;<lpage>e3729</lpage>. <pub-id pub-id-type="doi">10.1210/clinem/dgaa388</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>X. R.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Effect of tetrahedral DNA nanostructures on osteogenic differentiation of mesenchymal stem cells via activation of the Wnt/&#x3b2;-catenin signaling pathway</article-title>. <source>Nanomedicine</source> <volume>13</volume>, <fpage>1809</fpage>&#x2013;<lpage>1819</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2017.02.011</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bliuc</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Center</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Fractures in type 2 diabetes confer excess mortality: the Dubbo osteoporosis epidemiology study</article-title>. <source>Bone</source> <volume>159</volume>, <fpage>116373</fpage>. <pub-id pub-id-type="doi">10.1016/j.bone.2022.116373</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shuai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y. P.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Positive Effects of Qing&#x27;e Pill on Trabecular Microarchitecture and its Mechanical Properties in Osteopenic Ovariectomised Mice</article-title>. <source>Chin. J. Integr. Med.</source> <volume>25</volume>, <fpage>270</fpage>&#x2013;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-016-2604-0</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tickner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Cistanche deserticola polysaccharide attenuates osteoclastogenesis and bone resorption via inhibiting RANKL signaling and reactive oxygen species production</article-title>. <source>J. Cell Physiol.</source> <volume>233</volume>, <fpage>9674</fpage>&#x2013;<lpage>9684</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.26882</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Naringin promotes fracture healing through stimulation of angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in osteoporotic rats</article-title>. <source>Chem. Biol. Interact.</source> <volume>261</volume>, <fpage>11</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2016.10.020</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sozel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer</article-title>. <source>J. Oncol. Pharm. Pract.</source> <volume>27</volume>, <fpage>494</fpage>&#x2013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1177/1078155220940411</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shane</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Secondary osteoporosis</article-title>. <source>Endocrinol. Metabolism Clin. N. Am.</source> <volume>32</volume>, <fpage>115</fpage>&#x2013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/s0889-8529(02)00062-2</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <source>LBP1C-2 from Lycium barbarum alleviated age-related bone loss by targeting BMPRIA/BMPRII/Noggin</source>. <comment>Carbohydrate Polymers 310</comment>.</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Protective effects of Dipsacus asper polysaccharide on osteoporosis <italic>in vivo</italic> by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>129</volume>, <fpage>579</fpage>&#x2013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.02.022</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Cornus officinalis: a potential herb for treatment of osteoporosis</article-title>. <source>Front. Med.</source> <volume>10</volume>, <fpage>1289144</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2023.1289144</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tariq</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tariq</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lone</surname>
<given-names>K. P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Relationship of anthropometric measures with bone mineral density in postmenopausal non-osteoporotic, osteopenic and osteoporotic women</article-title>. <source>J. Pak Med. Assoc.</source> <volume>67</volume>, <fpage>590</fpage>&#x2013;<lpage>594</lpage>.</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>N. L.</given-names>
</name>
<name>
<surname>Eastell</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Leder</surname>
<given-names>B. Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial</article-title>. <source>Lancet Diabetes and Endocrinol.</source> <volume>7</volume>, <fpage>767</fpage>&#x2013;<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(19)30255-4</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vahle</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Sandusky</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Westmore</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose</article-title>. <source>Toxicol. Pathol.</source> <volume>32</volume>, <fpage>426</fpage>&#x2013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1080/01926230490462138</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Amerongen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mikels</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nusse</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Alternative wnt signaling is initiated by distinct receptors</article-title>. <source>Sci. Signal</source> <volume>1</volume>, <fpage>re9</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.135re9</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>VanderWalde</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hurria</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Aging and osteoporosis in breast and prostate cancer</article-title>. <source>CA Cancer J. Clin.</source> <volume>61</volume>, <fpage>139</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.3322/caac.20103</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vijayaraj</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Feltham</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rashidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>D. S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The ubiquitylation of IL-1&#x3b2; limits its cleavage by caspase-1 and targets it for proteasomal degradation</article-title>. <source>Nat. Commun.</source> <volume>12</volume>, <fpage>2713</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22979-3</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Curculigo orchioides polysaccharide COP70-1 stimulates osteogenic differentiation of MC3T3-E1 cells by activating the BMP and Wnt signaling pathways</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>248</volume>, <fpage>125879</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.125879</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z. R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway</article-title>. <source>Pharm. Biol.</source> <volume>60</volume>, <fpage>467</fpage>&#x2013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2022.2039216</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Timosaponin AIII attenuates inflammatory injury in AGEs-induced osteoblast and alloxan-induced diabetic osteoporosis zebrafish by modulating the RAGE/MAPK signaling pathways</article-title>. <source>Phytomedicine</source> <volume>75</volume>, <fpage>153247</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153247</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Naringin promotes osteogenesis and ameliorates osteoporosis development by targeting JAK2/STAT3 signalling</article-title>. <source>Clin. Exp. Pharmacol. Physiology</source> <volume>49</volume>, <fpage>113</fpage>&#x2013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1111/1440-1681.13591</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M.-S.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei&#x2014;an <italic>in vitro</italic> efficacy study</article-title>. <source>Phytomedicine</source> <volume>18</volume>, <fpage>868</fpage>&#x2013;<lpage>872</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2011.01.022</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Bushen Ningxin Decoction pharmacological serum promotes the proliferation and suppresses the apoptosis of murine osteoblasts through MAPK pathway</article-title>. <source>J. Ethnopharmacol.</source> <volume>122</volume>, <fpage>221</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2009.01.026</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Wnt signaling: a promising target for osteoarthritis therapy</article-title>. <source>Cell Commun. Signal</source> <volume>17</volume>, <fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/s12964-019-0411-x</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wayne Sampson</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Alcohol and other factors affecting osteoporosis risk in women</article-title>. <source>Alcohol Res. Health</source> <volume>26</volume>, <fpage>292</fpage>&#x2013;<lpage>298</lpage>.</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway</article-title>. <source>Eur. J. Pharmacol.</source> <volume>921</volume>, <fpage>174865</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.174865</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weivoda</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pederson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hachfeld</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davey</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Zajac</surname>
<given-names>J. D.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Osteoclast TGF-&#x3b2; receptor signaling induces Wnt1 secretion and couples bone resorption to bone formation</article-title>. <source>J. Bone Min. Res.</source> <volume>31</volume>, <fpage>76</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1002/jbmr.2586</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whyte</surname>
<given-names>M. P.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Paget&#x27;s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1068</volume>, <fpage>143</fpage>&#x2013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1346.016</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widmann</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Jarpe</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human</article-title>. <source>Physiol. Rev.</source> <volume>79</volume>, <fpage>143</fpage>&#x2013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.1999.79.1.143</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cline-Smith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shashkova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Perla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Katyal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aurora</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>T-cell mediated inflammation in postmenopausal osteoporosis</article-title>. <source>Front. Immunol.</source> <volume>12</volume>, <fpage>687551</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.687551</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>TGF-&#x3b2; and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease</article-title>. <source>Bone Res.</source> <volume>4</volume>, <fpage>16009</fpage>. <pub-id pub-id-type="doi">10.1038/boneres.2016.9</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Q.-c.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.-y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Z.-q.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H.-h.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.-s.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-&#x3b1; and GPR30 mediated p38 signalling pathway on MC3T3-E1 cells</article-title>. <source>Phytomedicine</source> <volume>68</volume>, <fpage>153146</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2019.153146</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells</article-title>. <source>Nat. Med.</source> <volume>18</volume>, <fpage>1095</fpage>&#x2013;<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2793</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2022</year>). <source>STK11 overexpression prevents glucocorticoid-induced osteoporosis via activating the AMPK/SIRT1/PGC1&#x3b1; axis</source>. <publisher-name>Human Cell</publisher-name>.</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Bioinformatics analysis combined with experimental validation to explore the mechanism of XianLing GuBao capsule against osteoarthritis</article-title>. <source>J. Ethnopharmacol.</source> <volume>294</volume>, <fpage>115292</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115292</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Effect of a derived herbal recipe from an ancient Chinese formula, Danggui Buxue Tang, on ovariectomized rats</article-title>. <source>J. Ethnopharmacol.</source> <volume>144</volume>, <fpage>567</fpage>&#x2013;<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2012.09.041</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Panayi</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>SHIP1 activator AQX-1125 regulates osteogenesis and osteoclastogenesis through PI3K/Akt and NF-&#x3ba;b signaling</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>10</volume>, <fpage>826023</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2022.826023</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Therapeutic effect of cistanoside A on bone metabolism of ovariectomized mice</article-title>. <source>Molecules</source> <volume>22</volume>, <fpage>197</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22020197</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Icariin promotes osteogenic differentiation by suppressing Notch signaling</article-title>. <source>Eur. J. Pharmacol.</source> <volume>865</volume>, <fpage>172794</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172794</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maxim</article-title>. <source>J. Ethnopharmacol.</source> <volume>192</volume>, <fpage>370</fpage>&#x2013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2016.07.037</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yahiro</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koinuma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jokoji</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ijuin</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl/Opg expression ratio in osteoblasts</article-title>. <source>Bone Res.</source> <volume>8</volume>, <fpage>32</fpage>. <pub-id pub-id-type="doi">10.1038/s41413-020-00106-0</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamakawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kusumoto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yuasa</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Stem cell aging in skeletal muscle regeneration and disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>1830</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21051830</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Mechanisms of zuogui pill in treating osteoporosis: perspective from bone marrow mesenchymal stem cells</article-title>. <source>Evidence-Based Complementary Altern. Med.</source> <volume>2018</volume>, <fpage>3717391</fpage>&#x2013;<lpage>3717398</lpage>. <pub-id pub-id-type="doi">10.1155/2018/3717391</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Mechanisms of zuogui pill in treating osteoporosis: perspective from bone marrow mesenchymal stem cells</article-title>. <source>Evid. Based Complement. Altern. Med.</source> <volume>2018</volume>, <fpage>3717391</fpage>. <pub-id pub-id-type="doi">10.1155/2018/3717391</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z. W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Ligustilide, a major bioactive component of Angelica sinensis, promotes bone formation via the GPR30/EGFR pathway</article-title>. <source>Sci. Rep.</source> <volume>9</volume>, <fpage>6991</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-43518-7</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Analysis of molecular mechanism of erxian decoction in treating osteoporosis based on formula optimization model</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2021</volume>, <fpage>6641838</fpage>. <pub-id pub-id-type="doi">10.1155/2021/6641838</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-&#x3ba;B signaling</article-title>. <source>Bone Res.</source> <volume>9</volume>, <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1038/s41413-021-00151-3</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>, <fpage>2604</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22052604</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.-j.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.-t.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-l.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-y.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>W.-x.</given-names>
</name>
<etal/>
</person-group> (<year>2018c</year>). <article-title>Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPAR&#x3b3;2 signaling in GIO rats</article-title>. <source>Acta Pharmacol. Sin.</source> <volume>39</volume>, <fpage>633</fpage>&#x2013;<lpage>641</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2017.134</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>A. X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Corylin, a flavonoid derived from Psoralea Fructus, induces osteoblastic differentiation via estrogen and Wnt/&#x3b2;-catenin signaling pathways</article-title>. <source>FASEB J.</source> <volume>34</volume>, <fpage>4311</fpage>&#x2013;<lpage>4328</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201902319RRR</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C. Y.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Osteoporosis: the result of an &#x27;aged&#x27; bone microenvironment</article-title>. <source>Trends Mol. Med.</source> <volume>22</volume>, <fpage>641</fpage>&#x2013;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2016.06.002</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C. Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Osteoporosis and periodontal diseases - an update on their association and mechanistic links</article-title>. <source>Periodontol</source> <volume>89</volume>, <fpage>99</fpage>&#x2013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1111/prd.12422</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>T. X. Y.</given-names>
</name>
<name>
<surname>Luu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>The shared KEGG pathways between icariin-targeted genes and osteoporosis</article-title>. <source>Aging (Albany NY)</source> <volume>12</volume>, <fpage>8191</fpage>&#x2013;<lpage>8201</lpage>. <pub-id pub-id-type="doi">10.18632/aging.103133</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R. T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Neutrophil-lymphocyte ratio is associated with arterial stiffness in postmenopausal women with osteoporosis</article-title>. <source>Arch. Gerontol. Geriatr.</source> <volume>61</volume>, <fpage>76</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.archger.2015.03.011</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>FoxO3a cooperates with RUNX1 to promote chondrogenesis and terminal hypertrophic of the chondrogenic progenitor cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>589</volume>, <fpage>41</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2021.12.008</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. T.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>Anti-osteoporotic activity of an edible traditional Chinese medicine cistanche deserticola on bone metabolism of ovariectomized rats through RANKL/RANK/TRAF6-Mediated signaling pathways</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1412</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01412</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z. D.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>G. Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>M. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>IGF-1R/&#x3b2;-catenin signaling axis is involved in type 2 diabetic osteoporosis</article-title>. <source>J. Zhejiang Univ. Sci. B</source> <volume>20</volume>, <fpage>838</fpage>&#x2013;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B1800648</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019c</year>). <article-title>Systems pharmacology dissection of action mechanisms of Dipsaci Radix for osteoporosis</article-title>. <source>Life Sci.</source> <volume>235</volume>, <fpage>116820</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116820</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling</article-title>. <source>Cell Death Dis.</source> <volume>12</volume>, <fpage>825</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-04110-y</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>W.-W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.-S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.-Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.-Y.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts</article-title>. <source>Maturitas</source> <volume>61</volume>, <fpage>334</fpage>&#x2013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2008.09.023</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>J.-B.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>UPLC/Q-TOF-MS-based metabolomics study of the anti-osteoporosis effects of Achyranthes bidentata polysaccharides in ovariectomized rats</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>112</volume>, <fpage>433</fpage>&#x2013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.01.204</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>N.-D.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.-K.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.-P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.-T.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Traditional Chinese medicine formulas for the treatment of osteoporosis: implication for antiosteoporotic drug discovery</article-title>. <source>J. Ethnopharmacol.</source> <volume>189</volume>, <fpage>61</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2016.05.025</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Insulin impedes osteogenesis of BMSCs by inhibiting autophagy and promoting premature senescence via the TGF-&#x3b2;1 pathway</article-title>. <source>Aging (Albany NY)</source> <volume>12</volume>, <fpage>2084</fpage>&#x2013;<lpage>2100</lpage>. <pub-id pub-id-type="doi">10.18632/aging.102723</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Anti-osteoporosis activity of a novel Achyranthes bidentata polysaccharide via stimulating bone formation</article-title>. <source>Carbohydr. Polym.</source> <volume>184</volume>, <fpage>288</fpage>&#x2013;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2017.12.070</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Reversing the imbalance in bone homeostasis via sustained release of SIRT-1 agonist to promote bone healing under osteoporotic condition</article-title>. <source>Bioact. Mater.</source> <volume>19</volume>, <fpage>429</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2022.04.017</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W. L. H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H. T.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>MAPK signal pathways in the regulation of cell proliferation in mammalian cells</article-title>. <source>Cell Res.</source> <volume>12</volume>, <fpage>9</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cr.7290105</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Berberine for bone regeneration: therapeutic potential and molecular mechanisms</article-title>. <source>J. Ethnopharmacol.</source> <volume>277</volume>, <fpage>114249</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114249</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway</article-title>. <source>J. Pharm. Pharmacol.</source> <volume>59</volume>, <fpage>1167</fpage>&#x2013;<lpage>1173</lpage>. <pub-id pub-id-type="doi">10.1211/jpp.59.8.0016</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tzeng</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Baicalin ameliorates dexamethasone-induced osteoporosis by regulation of the RANK/RANKL/OPG signaling pathway</article-title>. <source>Drug Des. Devel Ther.</source> <volume>14</volume>, <fpage>195</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S225516</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Exploring the mechanism of action Xianlingubao Prescription in the treatment of osteoporosis by network pharmacology</article-title>. <source>Comput. Biol. Chem.</source> <volume>85</volume>, <fpage>107240</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2020.107240</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/&#x3b2;-catenin pathway</article-title>. <source>Stem Cell Res. Ther.</source> <volume>10</volume>, <fpage>37</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-019-1143-y</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>L.-F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Evolving roles of natural terpenoids from traditional Chinese medicine in the treatment of osteoporosis</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>13</volume>, <fpage>901545</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.901545</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A mutation of cysteine 46 in IKK-&#x3b2; promotes mPGES-1 and caveolin-1 expression to exacerbate osteoclast differentiation and osteolysis</article-title>. <source>Biochem. Pharmacol.</source> <volume>172</volume>, <fpage>113762</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2019.113762</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>